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1. Introduction 
1.1 Influenza virus  
1.1.1 Structure and replication cycle 
Influenza A viruses are zoonotic pathogens which continuously circulate in several 
hosts including birds, pigs and humans (1). They belong to the family of 
Orthomyxoviridae and can be divided into influenza A, B and C viruses dependent 
on their viral antigens, whereby influenza A and B viruses are mostly relevant for 
humans (2-6). They are classified according to their hemagglutinin (HA) and 
neuraminidase (NA) properties. Currently, there are seventeen different HA and 
ten different NA protein subtypes known for influenza A viruses (1, 7). Their 
genome is composed of eight negative stranded RNA segments which encode 
eleven viral proteins (1): hemagglutinin (HA), neuraminidase (NA), matrix protein 1 
(M1), matrix protein 2 (M2), non-structural protein 1 (NS1), non-structural protein 2 
or nuclear export protein (NS2 or NEP), polymerase basic protein 1 (PB1), 
polymerase basic protein 2 (PB2), polymerase acidic protein (PA), nucleoprotein 
(NP) and polymerase basic protein 1-F2 (PB1-F2) (3). Influenza viruses are 80-
120 nm in diameter and roughly spherical (3, 8). HA, NA and M2 are integrated in 
the viral envelope, (Figure 1) which consists of a lipid bilayer, originally derived 
from the host cell. HA is the most abundant protein in the envelope which makes 
up to 80% of the surface molecules. It is important for the entrance of the virus by 
binding to the host cell receptor (3). NA is the second most abundant protein on 
the virus surface, which is important for proper budding to release virions from the 
host cell (1, 3). M2 forms tetramers and acts as an ion channel which acidifies the 
viral core in endocytosed vesicles, enabling virus uncoating (1), whereas M1 is 
located underneath the viral envelope, holding the viral ribonucleoproteins (vRNP) 
together (3). The vRNPs are composed of negative, single-stranded RNAs bound 
to a trimeric RNA polymerase complex (PA, PB1, PB2) on the terminal side. The 
remaining sequence is wrapped around multiple NPs forming a rod-shaped 
structure (9). 
Introduction 
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Figure 1: Schematic illustration of influenza A virus structure.  
Influenza virus is composed of eight single-stranded RNA segments which encode 11 different proteins:  
hemagglutinin (HA), neuraminidase (NA), matrix protein 1 (M1), matrix protein 2 (M2), non-structural protein 1 
(NS1), non-structural protein 2 or nuclear export protein (NS2 or NEP), polymerase basic protein 1 (PB1), 
polymerase basic protein 2 (PB2), polymerase acidic protein (PA), nucleoprotein (NP) and polymerase basic 
protein 1-F2 (PB1-F2). 
 
The influenza virus life cycle can be divided into five main stages: 1) entry of the 
virus into the host cell, 2) vRNP transport into the host cell nucleus and 3) 
replication of viral genes, 4) export of vRNPs to the cytoplasm, 5) assembly of viral 
proteins and vRNPs at the host cell membrane and budding (3). 
The initial step for virus propagation is the attachment to the host cell, via binding 
of HA to either α-2,6 or α-2,3 sialic acid (1). Human influenza virus strains primarily 
bind to α-2,6 sialic acid, in contrast to avian influenza viruses which mainly 
recognize α-2,3 linkages (3). In humans, the upper respiratory tract is primarily 
lined by α-2,6 sialic acid receptors, and α-2,3 sialic acid receptors are found in the 
lower, distal part (1).  
The virus is internalized by endocytosis and decrease of pH in the endocytic 
vesicle causes the ion channel M2 to open leading to release of vRNP complexes 
into the cytoplasm followed by translocation to the nucleus (1). Therefore, the 
proteins of the vRNP complex have a nuclear localization signal (3) and bind to 
cellular nuclear import complexes (3, 9). The negative single-stranded RNA of 
influenza viruses is converted to positive RNA strands, which then serve as a 
template for further viral RNA production (3). The negative sense vRNPs are 
exported by the nuclear pores and viral proteins and vRNP complexes associate 
with the host cell membrane, where viral particles are formed using the host cell 
plasma membrane. The final step for virion release is the sialic acid cleavage by 
NA which releases the virion from the apical side of polarized host cells (3, 10). 
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During influenza virus evasion, three major antiviral pathways are activated by 
host cells to limit infection (11), whereas influenza virus manipulates and 
counteracts host innate immune responses in order to replicate efficiently (12). 
The innate immune response which is primarily triggered by viral RNA initiates 
Toll-like receptors, inflammasome and retinoic acid inducible gene-1 (RIG-1) (11, 
13). Therefore, viral RNA is bound by RIG-1 and associates with mitochondrial 
associated antiviral signaling protein (MAVS) to induce NFκB (nuclear factor κ B) 
and interferon (IFN) production for viral clearance (11). Due to IFN production, the 
protein kinase R (PKR) is induced and usually gets activated by binding of dsRNA, 
which can initiate a general block of translation (14, 15). The viral NS1 protein is 
responsible for the inhibition of IFN production by limiting the activation of the 
transcription factor NFκB and dependent on the strain, also IRF3 (interferon 
regulatory factor 3) which is an interferon-inducible transcription factor (16, 17). 
Another cytoplasmatic antiviral protein which is activated by dsRNA binding is the 
2`-5`- oligoadenylate synthetase (OAS), that initiates the activation of RNase and 
thereby the inhibition of virus replication. NS1 is able to interact with both proteins 
to block their antiviral properties (18).  
 
1.1.2 Pathogenicity and epidemiology 
Influenza virus infection of the human respiratory tract can result in respiratory 
disease and may lead to death. At times, it is the most common cause of 
respiratory tract infections (19, 20). After infection, the host cell protein 
biosynthesis is shut down to focus on the production of viral proteins (21). 
Influenza virus can adapt to the host with certain strategies and is able to evolve 
minor changes in their surface proteins and thereby evade immune recognition by 
host neutralizing antibodies, which is called antigenic drift and results in host 
susceptibility to infection (22). Another modification of influenza viruses or even 
generation of new strains can occur by antigenic shift, which requires infection of 
one host with two influenza virus strains followed by reassortment of gene 
segments between the two strains (1).  
Influenza virus is usually airborne transmitted and causes a rapid onset of high 
fever, cough, headache, malaise and inflammation of the upper respiratory tract 
including trachea and upper respiratory tree, which persists for up to ten days. 
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Usually, people of all ages are affected, but severity is greatest in infants, aged 
persons and those with illness (19, 23). Interestingly, it has been demonstrated in 
an experimental approach that repair mechanisms after influenza infection are 
delayed in aged mice (24). In uncomplicated cases, influenza viruses only 
replicate in ciliated and non-ciliated cells of the nasal mucosa in the upper 
respiratory tract. Nevertheless, the virus can spread to the distal part of the lung, 
causing pneumonia with severe consequences. The cytolytic effect by the virus 
itself, or the indirect effects of host response causes damage of the alveolar 
epithelium, composed of type I and type II pneumocytes, leading to edema 
formation and severe respiratory dysfunction. Epidemics concerning all groups of 
ages occur each winter season, whereas worldwide pandemics appear irregularly 
(6). The most severe pandemic was the so-called spanish flu in 1918 which 
caused approximately 50 million deaths worldwide (2, 25).  
 
1.2 Acute lung injury and acute respiratory distress syndrome  
The most severe consequence which can result from influenza virus infection is 
the acute respiratory distress syndrome (ARDS) which was firstly described in 
1967 (26, 27). Since a standard definition for acute lung injury (ALI) and ARDS 
was made in 1994, the mortality rate did not remarkably change and still accounts 
for 30-40% (28-30). However, in the last years, new definition criteria for ARDS 
were addressed (31, 32) and a new categorization has been applied subdividing 
ARDS into mild, moderate, or severe. This is based on the degree of hypoxemia 
levels, according to the ratio between arterial oxygen concentration and the 
fraction of inspired oxygen (PaO2:FiO2) (32-34). Other criteria include a rapid onset 
and bilateral infiltrates, usually diagnosed by chest x-ray, with the exclusion of left 
arterial hypertension (35, 36).  
ARDS can have different causes. Some of the most common risk factors are 
pneumonia, sepsis, aspiration of gastric contents, inhalational injury and major 
trauma (36). The pathology can be divided into three main stages, which include 
the inflammatory, proliferative and fibrotic phase. The inflammatory phase is 
characterized by diffuse alveolar damage with disruption of the epithelial-
endothelial barrier and edema formation (37). The proliferative phase is defined by 
further damage to the alveolar epithelium and capillary network, where type II 
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pneumocytes start to proliferate to restore barrier function, and the alveolar air 
space is filled with cell debris and erythrocytes and fibroblasts become more 
apparent (38). The fibrotic phase includes deposition of collagen, fibronectin and 
extracellular matrix components and is characterized by an imbalance of pro- and 
antifibrotic factors which may stimulate lung resident fibroblast, and aberrant repair 
(31, 39, 40). 
The central role of ARDS treatment is protective ventilation, since mechanical 
ventilation can induce additional injury to the lung (41, 42). Severe life- threatening 
hypoxemia is treated by extracorporeal membrane oxygenation, if no other therapy 
is successful, to at least keep up oxygen levels and protect the lung (43, 44). 
Pharmacotherapeutic ARDS treatments include vasodilators, like nitric oxide which 
increases blood flow of ventilated alveoli, exogenous surfactant application, to 
decrease surface tension, or anti-coagulants to avoid thrombus formation to 
improve lung function (45, 46). Recent new therapies include mediators which 
promote cytoprotective or mitogenic effects, like KGF (keratinocyte growth factor) 
or GM-CSF (granulocyte/macrophage colony-stimulating factor) (47-49). 
Nowadays, also cell-based therapies with bone marrow derived mesenchymal 
stem cells are clinically tested. Nevertheless, new approaches for therapy of 
ARDS are required to decrease mortality rates and improve outcome (47, 50).  
 
1.3 Structural and cellular compartments of the lung 
The lung is a complex organ, which enables crucial oxygen supply and alterations 
in the lung structure may lead to impaired gas exchange (51). There is a clear 
hierarchy and branching morphometry in the lung (52). The human airway tree 
branches dichotomously about 23 times (51), which leads to about 480 million gas 
exchange units: the alveoli. This complex and delicate lung structure is supported 
by a fiber system which surrounds the entire conducting and alveolar structures 
(51). The upper, conducting airways are lined by bronchial epithelium (51). Ciliated 
cells remove potential harmful organisms or dust particles and filter the inhaled air 
by coordinated beating, whereas secretory cells, like goblet cells do not only keep 
the mucosa moist, but also bind particles and pathogens by their secreted mucus 
(53, 54). The bronchial epithelium contains club cells which produce surfactant 
(club cell 10 kDa secretory protein; CC10). They have multiple roles in lung 
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protection, for example by production of antimicrobial peptides or metabolism of 
toxic substances (54, 55). The alveolar compartment is lined by type I and type II 
pneumocytes. Type I pneumocytes are large squamous epithelial cells, which 
enable normal gas exchange (56). They are extraordinary thin (57) and share a 
basement membrane with the endothelial cells. The capillary is incorporated 
between the walls of two alveoli, allowing gas exchange on both sides of the 
septum (51). Type I pneumocytes cover 95% of alveoli, while they make up only 
8% of total cells (57). The cuboidal type II cells are mainly located in the corner of 
the alveolus and express surfactant proteins (57) which mostly consist of lipids 
and line the inner alveolar surface. Surfactants are important for alveolar stability 
and surface tension and therefore regulate proper ventilation (58). Another 
function is their contribution to host defense by binding surface structures of 
various pathogens to promote their elimination by alveolar macrophages (58). 
Microenvironmental factors, necessary for epithelial cells are provided and 
regulated by lung resident mesenchymal cells. They are not only important for 
secondary septa formation during development, they also regulate elastin and 
collagen deposition (59-61).  
 
1.4 Lung epithelial stem/progenitor cells 
The lung is a very complex organ which contains more than 40 different cell types 
(51, 62). Therefore, different region-specific epithelial progenitor cells have been 
detected in tracheobronchial, as well as in distal alveolar tissue (63). Due to slow 
turnover of epithelial cells in the lung, the proliferative response of lung epithelial 
progenitor cells are preferentially studied in injury models (62, 64). These different 
injury models, involving proximal airway, broncho- and/ or alveolar injury suggest 
that the adult lung contains different epithelial progenitor cell niches, which are 
characterized by self-renewal potential, clonogenicity and multipotency, 
representing classical properties of stem/progenitor cells (62, 63, 65). In general, 
stem cells can either divide symmetrically or asymmetrically. Symmetric division 
leads to generation of identical daughter cells, in contrast to asymmetric division 
which leads to the generation of terminally differentiated cells in addition to new 
progenitors (65-68). Furthermore, the local microenvironment or “niche” which 
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includes for example extracellular matrix and a broad spectrum of autocrine and 
paracrine factors, plays a crucial role in the regulation of stem cells (66, 69). 
 
1.4.1 Epithelial progenitor cells in rodents 
In the adult lung, various stem/progenitor cells are responsible for homeostasis of 
cells, as well as for the repair of injured lung tissue (70). In the cartilage containing 
tracheobronchial region, basal cells, defined by various markers, like nerve growth 
factor receptor, Krt5/14 (Cytokeratin 5/14), p63 (tumor protein 63) and aquaporin 3 
play an essential role during injury and can generate the major epithelial cell types 
found in the proximal airways, including basal cells, club cells, ciliated cells and 
goblet cells, which includes a Notch-mediated differentiation (71-76). Of note, cells 
located at the submucosal gland ducts (SMG), in between cartilage rings, are 
involved in repopulating processes of the SMG and its surface epithelium after 
injury. Therefore, the SMG is considered as a stem/progenitor cell niche (70, 77-
79). In the trachea and bronchioles, CC10-expressing club cells can be found, 
which respond differently during injury or homeostasis (80). Moreover, the majority 
of club cells express the cytochrome P450 which plays an important role in 
detoxification processes (55, 81, 82). Application of naphthalene causes severe 
bronchiolar damage to the epithelial cells due to cytochrome P450-mediated 
conversion into a toxic intermediate (83, 84). A small naphthalene resistant club 
cell subpopulation (vClub cells) is located at the distal conducting airways (83) 
which lacks the cytochrome P450 and contributes to airway repopulating 
processes after injury. It has been demonstrated that club cells give rise to ciliated 
cells and self-renew. In injury models of severe alveolar damage, club cells can 
also repopulate type II pneumocytes, most probably after a bronchiolar epithelium 
transitional state (69, 85, 86).  
A relatively undefined cell type is the neuroendocrine cell, located at airway 
branches or bronchoalveolar duct junctions (BADJ) and are usually clustered into 
neuroendocrine bodies (NEB). These cells are resistant to naphthalene injury and 
in close proximity to vClub cells, which suggests that the neuroendocrine body 
microenvironment habours a progenitor cell niche (87-89). Another cell population, 
located at the BADJ are the so-called bronchoalveolar stem cells (BASC), which 
were first described by Kim et al.. They express the type II pneumocyte marker 
Introduction 
13 
 
surfactant protein C (SP-C) and the club cell marker CC10. These cells are 
resistant to naphthalene treatment and increase in cell numbers after injury, which 
then return to baseline levels after restoration. Characterization of surface markers 
show a CD45negCD31negSca-1+CD34+ signature. In vitro experiments revealed that 
these cells can give rise to alveolar type I and type II pneumocytes, as well as club 
cells, which suggests that BASC self-renew but also habour the potential for 
multilineage differentiation (90). Interestingly, bronchopulmonary dysplasia, 
induced by hyperoxia treatment of newborn mice does not increase BASC 
numbers compared to normoxia controls, suggesting that not all types of injury 
stimulate BASC proliferation. However, additional factors, like bone marrow 
derived mesenchymal stromal cells or conditioned medium of these cells, increase 
the BASC population in hyperoxia-treated newborn mice, suggesting a contribution 
of paracrine factors (91).  
McQualter et al. defined a rare population with EpCamhighα6+β4+CD24low signature. 
This multipotent epithelial stem/progenitor cell (EpiSPC) fraction gives rise to 
airway or alveolar epithelial lineages in vitro suggesting an organized stem cell 
hierarchy in the adult murine lung (92, 93). Additionally, undifferentiated lung 
stromal cells, in contrast to α-smooth muscle actin+ (α-SMA+) myofibroblasts have 
a supportive influence on EpiSPC growth and upregulate genes which are 
associated with lung development, suggesting reactivation of developmental 
pathways during lung injury (94). Another progenitor cell type with the expression 
of integrin α6β4 was proposed by Chapman et al.. These cells clonally expand and 
proliferate ex vivo. This rare population possesses the ability to proliferate and 
form organoid structures after kidney capsule implantations (95). 
Of note, it has been demonstrated that p63+Krt5+ expressing cells undergo rapid 
proliferation after influenza virus infection. These cells form clusters ("pods") which 
are found in interbronchial regions of damaged tissue (96). Lineage tracing studies 
of p63+ cells after influenza virus infection or bleomycin treatment show that the 
majority of newly generated p63+ cells derived from CC10+ cells and not from pre-
existing p63+ basal cells located in the upper airways (97). These so-called distal 
airway stem cells (DASC) differentiate into alveolar and bronchiolar lung tissue, 
and selective depletion of these cells impairs the regenerative process in vivo (98). 
Another report describes migration and co-expression of α6β4+ cells in 
combination with Krt5, in influenza virus-challenged lung tissue and excludes the 
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contribution of basal cells for Krt5+p63+ pods. These lineage-negative epithelial 
progenitors (LNEP) are an important responder after severe lung injury. 
Interestingly, ex vivo culture of LNEP alone, or with various morphogenic factors 
does not stimulate Krt5 expression, in contrast to culture with bronchoalveolar 
lavage fluid (BALF) of influenza virus-infected mice which results in proliferation 
and Krt5 upregulation (99), suggesting that multiple factors induced in the stem 
cell niche contribute to their regenerative response. The distal lung is lined by two 
cell types, the squamous type I pneumocytes which enable gas exchange and the 
cuboidal surfactant protein-producing type II pneumocytes (100). Since a long time 
it has been suggested that type II pneumocytes act as progenitors for type I 
pneumocytes (101). A recent report demonstrates the self-renewal abilities of type 
II pneumocytes and differentiation into cells that express type I pneumocyte 
markers after bleomycin-induced injury (102), representing an important alveolar 
progenitor cell activated after mild injury. 
Although the presence of different epithelial progenitor cell populations is well 
described, their lineage relation and particularly their defined roles in replenishing 
different epithelial components of the lung after injury is not well defined. In 
addition, the signals which stimulate them to drive coordinated repair processes 
without aberrant wound healing is still not well understood.  
 
 
 
Figure 2: Schematic illustration of epithelial stem/progenitor cells in the murine lung. 
Epithelial stem/progenitor cells of the adult murine lung are located at side-specific regions from the 
tracheobronchial until the distal alveolar tissue. They contribue to tissue repair processes after injury and are 
characterized by self-renewal, multipotency and clonogenicity; BASC, bronchoalveolar stem cell; DASC, distal 
airway stem cells; LNEP, lineage-negative epithelial progenitor; NEB, neuroendocrine bodies; SMG, 
submucosal gland; vClub cell; variant club cell. 
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1.4.2 Epithelial progenitor cells in the human lung 
Although, the epithelial stem cell research in the adult murine model is well 
established, much less is known about epithelial progenitor cells in the adult 
human lung. In particular, the knowledge about defined markers to isolate a 
homogenous population is very limited (103). It has been described that different 
airway epithelial cells of the bronchial epithelium in the upper respiratory tract have 
the ability to form submucosal glands in xenograft models (104). In the 
tracheobronchial region, a side population of CD45neg cells is identified with 
clonogenic capacity. These cells express epithelial cell markers, like Krt5, E-
cadherin, ZO-1 (zona occludens protein 1), p63 and are isolated according to their 
property to efflux hoechst stain (105). The hoechst stain is a vitality staining and 
primarily used to determine the DNA content for cell cycle studies, but it can be 
used to identify cells with stem or progenitor abilities (106). In the pseudostratified 
epithelium, p63+ cells can be found, which are morphologically comparable to 
murine basal cells. These cells are able to either self-renew or differentiate into 
luminal or ciliated cells in vitro which is dependent on the Notch signaling pathway 
(72, 73). In the distal lung, it is demonstrated that type II pneumocytes form 
spheres in co-culture with a human lung fibroblast cell line (MRC-5), suggesting 
clonality and self-renewal properties of type II pneumocytes. Of note, culture of 
type II pneumocytes alone does not result in spheric outgrowth. Histological 
analysis revealed that most of the cells express the type II pneumocyte-specific 
membrane protein HTII-280 (102, 107). Another report describes the identification 
of multipotent human lung stem cells with the stem cell marker c-kit (mast/stem 
cell growth factor  receptor kit). Cultured multicellular clones are negative for 
specialized cell types, like epithelial, smooth muscle, and endothelial cell markers 
but express NANOG (homeobox protein NANOG), Oct3/4 (octamer binding 
transcription factor 3/4), Sox2 (sex determining region Y-box2) and Klf4 (krueppel-
like factor 4), and show mutipotency, clonogenicity and self-renewal capacity. 
Injection of these c-kit+ cells into damaged mouse lung tissue result in the 
formation of bronchioles, alveoli and pulmonary vessels in vivo (65). Terminal 
bronchoalveolar tissue is generated by single cell injections of E-cadherin+/lgr6+ 
(leucine-rich repeat containing G protein-coupled receptor) human epithelial lung 
cells into kidney capsules (103). Of note, the E-cadherin+/lgr6+ cell population is a 
subpopulation of integrin α6+ cells, which show self-renewal and differentiation into 
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specialized epithelial cells, but not mesenchymal or endothelial differentiation 
(103).  
 
1.5 Fibroblast growth factors and corresponding receptors 
The first fibroblast growth factors (Fgf) were isolated from brain and pituitary gland. 
They were termed Fgfs due to their mitogenic activity on cultured fibroblasts (108-
110). Today, the mammalian Fgf family comprises 22 members of structurally 
related polypeptides, which can be divided by their mode of action into endocrine, 
paracrine and intracrine members. The endocrine and paracrine Fgfs act via a cell 
surface tyrosine receptor, in contrast to the intracrine Fgfs which act intracellularly 
and independent of a receptor (111). The family of paracrine Fgfs is the largest 
family which comprises four subfamilies, including Fgf7 and Fgf10. Most of the 
paracrine Fgfs are secreted proteins and mediate biological responses by binding 
to cell surface tyrosine kinase receptor with heparin/heparan sulfate which acts as 
a cofactor and ensures stable interaction and signaling (111-113). The Fgf 
receptors are composed of an extracellular domain which is responsible for ligand 
binding, a transmembrane domain and an intracellular domain with the tyrosine 
kinase core as well as regulatory sequences (112). The extracellular ligand 
binding domain consists of immunoglobulin-like domains which can be 
alternatively spliced (112, 113). Four fibroblast growth factor receptor (Fgfr) genes 
have been identified, but due to splicing seven major forms exist with different 
ligand-binding specificities (1b, 1c, 2b, 2c, 3b, 3c, 4)  (111, 112). The isoform b of 
the Fgfr is preferentially expressed by the epithelium, whereas the c isoform of the 
receptor is expressed mainly by mesenchymal cells (114, 115). Ligand binding 
induces functional dimerization, phosphorylation of tyrosine residues on the 
receptor, and activation of four major downstream signaling pathways RAS-RAF-
MAPK, PI3K-AKT, STAT and PLCγ and may lead to migration, survival and 
proliferation (116).  
 
1.6 Fibroblast growth factor 10 in the embryonic and adult lung 
During lung organogenesis, Fgf10 is expressed in the distal mesenchyme where it 
activates the epithelial Fgfr2b to induce branching of the local epithelium whereat 
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Fgf10 dosage seems to be critical in the epithelial amplification process (117-119). 
The importance of Fgf10/Fgfr2b signaling during lung development is 
demonstrated in respective knockout animals which are not viable after birth. The 
absence of the receptor Fgfr2b or its ligand Fgf10 result in a wide range of 
phenotypic abnormalities in multi-organ development of all three germ layers 
including lung development failure, and the phenotype of Fgf10 knockouts 
correlates with Fgfr2b null mice (120-123). Fgf10 is structurally most related to 
Fgf7 (also known as keratinocyte growth factor; KGF) and both bind to the Fgfr 
isoform Fgfr2b which is present on epithelial components of various tissues 
including lung (123, 124). But in contrast to Fgf10-/- or Fgfr2b-/- animals, Fgf7-/- 
animals display not such remarkable abnormalities during lung development (120, 
124-126). Of note, Fgf7 can only activate Fgfr2b, whereas Fgf10 is able to bind to 
Fgfr2b and Fgfr1b. However, Fgfr1b knockout animals do not show a lung-specific 
phenotype (112, 127), suggesting a minor importance of Fgfr1 in lung 
development or repair. Interestingly, Fgfr2b stimulation with different ligands 
results in different responses. Stimulation with Fgf7 results in rapid receptor 
degradation, whereat stimulation with Fgf10 results in prolonged signaling and 
receptor recycling (128). 
During lung development, Fgf10 is secreted by mesenchymal progenitor cells, and 
acts on distal epithelial progenitor cells to keep them in a progenitor phenotype by 
preventing differentiation (129, 130). Furthermore, Fgf10 acts as chemoattractant 
for distal lung epithelial cells in a mesenchymal-free environment, promotes 
endodermal outgrowth and induces budding (131, 132). Inhibition with a dominant 
negative, soluble Fgfr2, which binds several ligands, including Fgf10, reveals a 
time-dependent Fgf requirement for lung formation, whereat postnatal suppression 
of Fgf signaling has no remarkable effect on late alveologenesis (133). However, 
in the adult lung it has been demonstrated that parabronchial smooth muscle cells 
get reactivated by epithelial Wnt7b (wingless-type, mouse mammary tumor virus 
(MMTV) integration site family, member 7B) signaling to express Fgf10 after 
epithelial injury caused by naphthalene. This paracrine Fgf10 signaling activates 
the remaining airway progenitor cell pool to proliferate and to promote restoration 
of the lung barrier. Interestingly, parabronchial smooth muscle precursors 
represent one of the pools for Fgf10 expression during development (129, 134). 
This demonstrates the ability to reactivate developmental pathways in the adult 
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lung after injury and to promote epithelial repair (134-136). In another lung injury 
model, induced by profibrotic bleomycin, Fgf10 overexpression in inducible 
transgenic animals attenuates the fibrotic phenotype, resulting in less collagen 
deposition, increased survival, and protection of epithelial cells (137). It also has 
been shown that overexpression of a soluble, dominant negative Fgfr2 expressed 
under the surfactant protein C (SP-C) promoter increases alveolar permeability, 
inflammatory cytokine expression and decreases surfactant protein expression. 
Additionally, adult mice fail to recover after hyperoxia treatment, when the 
dominant negative Fgfr2b is expressed (133, 138).  
 
1.7 Aim of the thesis work 
Influenza virus causes respiratory tract infections which may lead to acute lung 
injury or its severe form, the acute respiratory distress syndrome (ARDS). ARDS is 
characterized by epithelial cell apoptosis, disruption of the epithelial layer and 
edema formation which impairs gas exchange dramatically. The pathological 
consequences of influenza virus infection are well described, but regenerative 
pathways and host-pathogen interactions during these processes are poorly 
understood. Epithelial progenitor cells have been shown to proliferate after injury 
and contribute to repair processes to restore lung architecture and function.  
The aim of this work was to investigate if repair processes after influenza virus 
infection are dependent on a distinct pool of distal epithelial progenitor cells, and 
thereby evaluating the role of contributing regenerative signaling pathways. 
Furthermore, the interaction between virus and host cell-mediated regenerative 
pathways is elucidated to finally find new therapeutic approaches to foster repair 
processes after influenza virus infection. Therefore, evaluation of the proliferative 
potential and differentiation properties of distal epithelial progenitor cells in three-
dimensional cultures, as well as in in vivo mouse models with wildtype, inducible 
genetically modified, or knockout animals were performed. 
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2. Materials & Methods 
2.1 Cell culture media  
Medium  Ingredients 
Avicel overlay medium 2xMEM (Gibco), 0.1% NaHCO3 (Sigma-Aldrich), 
0.2% BSA (Sigma-Aldrich), 1.25% Avicel (FMC 
Biopolymers), 1x penicillin/streptomycin (Sigma-
Aldrich), 1 µg/ml trypsin TPCK (Worthington). 
Basal medium 2 Basal Medium (Promocell), 0.02 ml/ml FBS 
(Promocell), recombinant human insulin [1 ng/ml] 
(Promocell), recombinant human basic FGF [5 
µg/ml] (Promocell), 1x penicillin/streptomycin 
(Sigma-Aldrich). 
DMEM/HEPES DMEM (Gibco), 25 mM HEPES (Biochrom). 
EpiSPC basic medium MEM-alpha (Gibco), 10% FBS (Gibco), 1x insulin/ 
transferrin/ selenium (Gibco), 1x 
penicillin/streptomycin (Sigma-Aldrich), 0.0002% 
heparin (Stemcell Technologies), 2 mM L-glutamine 
(PAA). 
EpiSPC expansion 
medium (murine and 
human) 
EpiSPC basic medium, 50 ng/ml recombinant 
human Fgf10 (R&D Systems), 30 ng/ml recombinant 
murine or human HGF (R&D Systems). After 
influenza virus infection 1 µg/ml trypsin TPCK 
(Worthington) was added to the medium. 
hAEC medium F12 Nutrient Mixture (Ham) (Gibco), 10% FBS 
(Gibco), 1x penicillin/streptomycin (Sigma-Aldrich),  
2.5 µg/ml amphotericin B (PAA). 
Human co-culture 
medium 
MEM-alpha (Gibco), 2% FBS (Gibco), 1x insulin/ 
transferrin/ selenium (Gibco), 1x 
penicillin/streptomycin (Sigma-Aldrich), 0.0002% 
heparin (Stemcell Technologies), 2 mM L-glutamine 
(PAA). 
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Medium  Ingredients 
Infection medium DMEM (Gibco), 1x penicillin/streptomycin (Sigma-
Aldrich), L-glutamine (PAA), 0.2% BSA (Sigma-
Aldrich), 1 µg/ml trypsin TPCK (Worthington). 
Inoculation medium PBSMg+/Ca+ (Gibco), 0.2% BSA (Sigma-Aldrich), 1x 
penicillin/streptomycin (Sigma-Aldrich). 
mAEC medium DMEM (Gibco), 25 mM HEPES (Biochrom), 10% 
FBS (Gibco), 1x penicillin/streptomycin (Sigma-
Aldrich). 
MDCK.2 medium DMEM (Gibco), 10% FBS (Gibco), 1x 
penicillin/streptomycin (Sigma-Aldrich). 
 
2.2 Buffers and solutions 
Buffers /Solutions Ingredients 
FACS buffer 920 ml PBS-/- (Gibco), 74 ml 1% EDTA (Biochrom), 5 
ml FBS (Gibco), 10 ml 9% Na-azide (Sigma-Aldrich), 
sterile filtered, pH= 7.4. 
MACS buffer 920 ml PBS-/- (Gibco), 74 ml 1% EDTA (Biochrom), 5 
ml FBS (Gibco), sterile filtered, pH=7.4. 
PII-Solution 7.95 g/l NaCl (Carl Roth GmbH), 0.4 g/l KCl (Merck), 
1.11 g/l glucose (Sigma-Aldrich), 0.46 g/l Na2HPO4 
(Merck), 2.38 g/l HEPES (Sigma-Aldrich), 0.28 g/l 
CaCl2 x 2H2O [2mM] (Sigma-Aldrich), MgSO4 x 
7H2O (Fluka) [1.3 mM] diluted in H2O (B. Braun), 
pH= 7.2, sterile filtered. 
Paraformaldehyde 
(PFA) 4% 
4 g PFA (Sigma-Aldrich) in 100 ml PBS-/- (Gibco), 
pH= 7.4. 
PBS/EDTA 2 mM EDTA (Biochrom) in PBS-/- (Gibco), sterile 
filtered. 
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2.3 Transgenic mouse strains 
The following mice strains were used for experimentation.  
Mouse strain Features 
C57BL/6N  Wildtype (WT) 
Rosa26rtTA/+;tet(O)sFgfr2b/+ Inducible overexpression of soluble, dominant 
negative Fgfr2b  
Rosa26rtTA/+;tet(O)Fgf10/+ Inducible Fgf10 overexpression 
Fgf7-/- Fgf7 knockout 
 
Generation of Rosa26 rtTA mice was achieved by crossing CMV-Cre mice with 
rtTAflox mice (139, 140), which resulted in a ubiquitous expressed rtTA under the 
Rosa26 promoter. This constitutive Rosa26rtTA/+ strain was crossed with either 
tet(O)sFgfr2b (133, 141) or tet(O)Fgf10 (134, 142) responder lines to allow 
expression of either soluble, dominant negative Fgfr2b or Fgf10 when doxycycline 
containing food (625 mg/kg, Harlan Teklad) was administered. Rosa26rtTA/+; 
tet(O)sFgfr2b/+ and Rosa26rtTA/+; tet(O)Fgf10 heterozygous mice were generated 
on a mixed background and genotyped as previously described (133, 140, 142, 
143). Fgf7 knockout animals were purchased from Jackson Laboratories (stock 
number 4161) on a mixed background and backcrossed for five generations into a 
C57BL/6N background. Animal experiments performed at the Justus-Liebig 
University were approved by regional authorities of the State of Hesse 
(Regierungspräsidium Giessen). 
 
2.4 Influenza virus strains 
The following virus strains were used for the experimental part: 
Virus strain Characteristics 
A/Puerto Rico/8/34 
(A/PR8) 
H1N1 adapted to mice 
by passaging 
A/X-31(H3N2) 
(x-31) 
H3N2 in a A/PR8 
backbone 
A/Hamburg/04/09 
(pH1N1) 
H1N1 pandemic, 
human isolate 
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2.5 Human lung tissue 
Human lung tissue was obtained from patients undergoing lobectomy for tumor 
removal after written consent in cooperation with the departments of Pathology 
and Surgery, Justus-Liebig-University, Giessen. Processing of human lung tissue 
was approved by the Ethics Committee of the University Giessen (Az. 10/06). 
 
2.6 Preparation of virus stock  
For the preparation of a virus stock, MDCK.2 cells (Madin darby canine kidney 
cells; ATCC number CRL-2936) were passaged. Therefore cells were washed 
twice with PBSMg+/Ca+ (Gibco) and trypsin EDTA (Biochrom) was added until the 
cells detached from the T75 culture flask (Greiner Bio-one), followed by addition of 
MDCK.2 medium and further incubation at 37°C, 5% CO2. After  4h (confluency   
80%), cells were infected with a MOI (multiplicity of infection) of 0.01. Therefore, 
cells were washed twice with PBSMg+/Ca+ (Gibco) and 4 ml of inoculum were added 
to the cells, followed by incubation at room temperature for 1h. The inoculum was 
removed and infection medium was added to the cells, followed by additional 
incubation for 48h at 37°C, 5% CO2. The infection medium was collected and 
centrifuged to remove cell debris (4,000 rpm, 15 min, 4°C). The supernatant was 
aliquoted and stored at -80°C until quantification of virus titers were performed. 
 MOI calculation:    Virus (plaque-forming units)    
                  Cell number 
 
2.7 Quantification of virus concentration  
To quantify virus concentration, a plaque assay was performed. MDCK.2 cells 
were passaged and seeded in 6-well plates (Greiner bio-one) one day prior 
infection. The cells were washed with PBSMg+/Ca+ (Gibco) and a dilution series of 
the virus stock or BALF was made and 1 ml of the inoculum was added to the 
MDCK.2 cells, followed by incubation at room temperature for 1h. 2 ml Avicel 
overlay medium were added to the cells, followed by incubation for 48h at 37°C, 
5% CO2. The Avicel overlay medium was removed, and cells were fixed with 1 ml 
4% paraformaldehyde (PFA, Sigma-Aldrich) for 30 min at 4°C, followed by three 
times washing with PBSMg+/Ca+ (Gibco). After permeabilization with 1 ml of 0.3% 
Triton-X 100 (Roth) for 15 min at room temperature, 0.5 ml of the primary 
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antibody, detecting influenza A nucleoprotein (NP) 1:1000 (Meridian Life Science) 
in PBSMg+/Ca+ (Gibco), 0.1% Tween-80 (Sigma-Aldrich), 10% horse serum (PAA) 
was added and incubated for 1h at room temperature, followed by three times 
washing with PBSMg+/Ca+ (Gibco), 0.05% Tween-80 (Sigma-Aldrich). After addition 
of 0.5 ml of the secondary antibody (goat α-mouse horseradish peroxidase, Santa 
Cruz) in a 1:2000 dilution (diluent: PBSMg+/Ca+ (Gibco) in 0.1% Tween-80 (Sigma-
Aldrich), 10% horse serum (PAA)), cells were incubated for 1h at room 
temperature, followed by three times washing with PBSMg+/Ca+ (Gibco), 0.05% 
Tween-80 (Sigma-Aldrich). After addition of the peroxidase substrate (True Blue, 
KPL) and incubation for 15-30 min, plaques were detected. The reaction was 
stopped by washing with H2O (B. Braun) and plates were dried and stored at room 
temperature. The quantification of virus stocks or BALF was always performed in 
duplicates.  
 
2.8 Quantitative real-time PCR 
FACS sorted or cultured cells were washed once with PBSMg+/Ca+ followed by lysis 
with RLT buffer (Qiagen). RNA isolation was performed using RNeasy Kit (Qiagen) 
according to manufacturer's manual. After extraction, RNA concentration and 
quality were measured by Nanovue Plus (GE Healthcare). cDNA synthesis was 
prepared with a total volume of 13.5 µl containing 250 ng RNA in dH2O (5 prime 
GmbH) which was denatured at 70°C for 5 min, followed by addition of 11.5 µl 
PCR mixture to the samples.  
 
PCR mixture: 
5x First stand buffer (Invitrogen) 5 µl 
0.1 M Dithiothreitol (DTT) (Invitrogen)  2.5 µl 
Random primer (Boehringer) 1.5 µl 
Recombinant ribonuclease inhibitor 40 U/µl (Invitrogen) 0.5 µl 
PCR Nucleotide Mix (Roche)  1 µl 
M-MLV Reverse Transcriptase 200 U/µl (Invitrogen) 0.75 µl 
dH20 (5 Prime GmbH) 0.25 µl 
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Samples were incubated in a thermocycler machine (Peqlab) for 1h at 37°C until 
reaction was stopped by heating up the samples for 5 min at 95°C. cDNA was 
diluted in a 1:3 ratio with dH2O (5 Prime GmbH) for qRT-PCR reaction. β-actin or 
ribosomal protein subunit S-18 (RSP18) expression served as normalization 
control. The reactions were performed with SYBR green I (Invitrogen) in the AB 
Step one plus Detection System (Applied Bioscience) with intron-spanning 
primers. The following qRT-PCR mixture was used for a reaction: 
 
qRT-PCR mixture: 
Sybr Green (Invitrogen) 13 µl 
Forward primer [10 pmol/µl] 0.5 µl 
Reverse primer [10 pmol/µl] 0.5 µl 
50 mM MgCl2 (Invitrogen) 1 µl 
dH2O (5 Prime GmbH) 5 µl 
 
The following intron spanning primers were used for quantitative RT-PCR: 
Gene Primer sequence 
murine Actin forward 
murine Actin reverse 
5′-ACCCTAAGGCCAACCGTGA-3′ 
5′-CAGAGGCATACAGGGACAGCA-3′ 
murine Aquaporine 5 forward 
murine Aquaporine 5 reverse 
5’-TGGGGATCTACTTCACCGGC-3′ 
5’-TACCCAGAAGACCCAGTGAGAGG-3′ 
murine β-tubulin forward 
murine β-tubulin reverse 
5’-CCACCACCATGCGGGAAA-3′ 
5’-CTGATGACCTCCCAGAACTTG-3′ 
murine Ccnd1 forward 
murine Ccnd1 reverse 
5’- GCGTACCCTGACACCAAT-3′ 
5’- GGTCTCCTCCGTCTTGAG-3′ 
murine CC10 forward 
murine CC10 reverse 
5’-CAGACACCAAAGCCTCCAACC-3′ 
5’-GGGCAGATGTCCGAAGAAGC-3′ 
murine Fgf7 forward 
murine Fgf7 reverse 
5’- TCGCACCCAGTGGTACCTG-3′; 
5’- ACTGCCACGGTCCTGATTTC- 3’ 
murine Fgf10 forward 
murine Fgf10 reverse 
5’-CCATGAACAAGAAGGGGAAA-3′ 
5’-CCATTGTGCTGCCAGTTAAA-3′ 
murine Krt5 forward 
murine Krt5 reverse 
5’-CCTTCGAAACACCAAGCACG-3′ 
5’-AGGTTGGCACACTGCTTCTT-3′ 
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Gene Primer sequence 
murine Podoplanin forward 
murine Podoplanin reverse 
5’-CCCCAATAGAGATAATGCAGGGG-3′ 
5’-GCCAATGGCTAACAAGACGC-3′ 
murine proSP-C forward 
murine proSP-C reverse 
5’-TCCTGATGGAGAGTCCACCG-3′ 
5’-CAGAGCCCCTACAATCACCAC-3′ 
murine p63 forward 
murine p63 reverse 
5’-CAAAGAACGGCGATGGTACG-3′ 
5’-CCTCTCACTGGTAGGTACAGC-3′ 
murine RPS-18 forward 
murine RPS-18 reverse 
5’- CCGCCATGTCTCTAGTGATCC-3′ 
5’- TTGGTGAGGTCGATGTCTGC-3′ 
The relative gene abundance compared to the housekeeping gene was calculated 
as ΔCt value (Ctreference – Cttarget). Comparison with control cells are presented as 
ΔΔCt (ΔCtreference - ΔCttarget). Data are presented as ΔCT or ΔΔCt. 
 
2.9 Immunohistochemistry and immunofluorescence 
For the preparation of cryosections, lungs were perfused with HBSS (Gibco) and 
filled with 1.5 ml Tissue Tek (O.C.T. Compounds, Sakura) mixed with PBS-/- 
(Gibco) in a 1:1 ratio. The lungs were embedded in Tissue Tek (Sakura) and snap-
frozen in liquid nitrogen. 3-4 µm slices were cut with a Leica CM 1850 UV 
Cryotome and the slides were stored at -20°C. Lung sections or cytospins of 
FACS sorted cells were Hematoxylin-Eosin (H&E) or Pappenheim stained 
according to the following protocols. 
For the H&E staining the cryosections were put in Hematoxylin solution (modified 
according to Gill III, Merck) for 10 to 20 sec. Slides were washed with tap water 
until staining solution was removed, followed by differentiation in 1% actetic acid 
for 10 sec and washing with tap water. After that, the slides were dipped in dH2O 
(B. Braun) and stained with Eosin G-solution (0.5% aqueous, Merck) for 10-15 
sec, followed by a stepwise dehydration with 70%, 96% and 100% ethanol (J.T. 
Baker). 
For the Pappenheim staining, cytospins were stained with May Grünwald (Merck) 
for 5 min, followed by short washing with dH2O (B. Braun). After that, the slides 
were stained for 10 min in Giemsa’s azur eosin methylene blue solution (Merck) 
and finally washed with dH2O (B. Braun) and subsequently dried and mounted 
(Neo-mount, Merck). 
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For immunofluorescence stainings, lung sections were fixed with 4% PFA (Sigma-
Aldrich) for 20 min and subsequently incubated with 0.05% Tween-20 (Sigma-
Aldrich), 5% BSA (Sigma-Aldrich), 5% horse serum (PAA) in PBS-/- for 30 min. 
Fluorochrome-labeled antibodies or corresponding isotype control antibodies were 
diluted in PBS-/-, 0.1% BSA, 0.02% Triton X-100 (Roth) and incubated for 2h. For 
non-labeled antibodies the slides were washed with PBS-/-, 0.1% BSA, 0.02% 
Triton X-100 (Roth) and incubated with corresponding fluorochrome-labeled 
secondary antibodies for 2h, followed by mounting with dapi-containing mounting 
medium (Vectashield, Vector Labs). Cultured cells were fixed in a 1:1 ratio of ice-
cold acetone/methanol for 5 min and subsequently incubated with 3% BSA in  
PBS-/- for 30 min. Cells were stained with primary or isotype control antibodies, 
respectively, followed by addition of corresponding secondary antibodies for 2h 
and mounting with dapi-containing mounting medium. Images were taken with a 
Leica DM 2000 microscope using the Leica digital imaging software LAS. The 
following antibody dilutions were applied: 
 
Immunofluorescence stainings:  
Primary Antibodies Dilution 
α-SMA FITC (clone: 1A4, Sigma-Aldrich) 1:100 
β-IV-tubulin (clone: ONS.1, Abcam) or isotype control 
IgG1 (clone: CT6, Abcam) 
1:50 
CC10 (clone: T-18, Santa Cruz) and isotype control 
normal goat IgG (Santa Cruz) 
1:100 
CD49f PE (clone: GoH3, Biolegend) 1:50 
E-cadherin (clone: DECMA-1, Abcam) 1:200 
EpCam FITC (clone: G8.8, Biolegend) 1:20 
Keratin 5 FITC (Bioss) 1:100 
Ki67 (Thermo Scientific) 1:100 
Mucin5ac biotin (clone: 45M1, Abcam) 1:50 
p63 protein A-555 (clone: P51A, Bioss) 1:100 
pro-surfactant protein C (Millipore) or rabbit serum 
(Sigma-Aldrich) 
1:500 
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Secondary Antibodies Dilution 
anti-streptavidin-APC (BD Pharmingen) 1:50 
chicken anti-goat IgG Alexa Fluor 488 (Invitrogen) 1:800 to 1:1000 
chicken anti-goat IgG Alexa Fluor 647 (Invitrogen) 1:800 to 1:1000 
donkey anti-mouse IgG Alexa Fluor 555 (Invitrogen) 1:500 
donkey anti-rabbit IgG Alexa Fluor 555 (Invitrogen) 1:800 
donkey anti-rabbit IgG Alexa Fluor 488 (Invitrogen) 1:800 to 1:1000 
donkey anti-rabbit IgG Alexa Fluor 647 (Invitrogen) 1:800 to 1:1000 
donkey anti-rat IgG Alexa Fluor 555 (Abcam) 1:800 to 1:1000 
donkey anti-rat IgG Alexa Fluor 488 (Invitrogen) 1:1000 
 
2.10 Quantitative flow cytometry and FACS sorting   
Multicolor flow cytometry or fluorescence activated cell sorting was performed with 
the LSR Fortessa (BD Bioscience) and the Aria III (BD Bioscience) using DIVA 
software (BD Bioscience) or Flowing Software. For analytical measurements 1-5 x 
105 cells were freshly stained with fluorochrome-labeled antibodies for 20 min at 
4°C. For intracellular stainings, permeabilization of cells was achieved by previous 
incubation with 0.2% saponin (Calbiochem) diluted in FACS buffer for 20 min at 
4°C, followed by incubation with respective antibodies or isotype controls for 20 
min at 4°C. For stainings with non-labeled primary antibodies, a fluorochrome-
labeled secondary antibody was added and incubated for 20 min at 4°C. Finally, 
the cells were resuspended in the corresponding buffer. Annexin V staining for 
apoptosis measurements was performed on unfixed, non-permeabilized cells. 
Prior to antibody incubation, cells were washed and resuspended in Annexin V 
buffer (BD Bioscience) and incubated with Annexin V Alexa Fluor 647 and 
respective antibodies for 20 min at 4°C, followed by resuspension in Annexin V 
buffer. For the LipidTox staining (Invitrogen), cells were first stained with 
antibodies, followed by fixation in 4% PFA and incubation with diluted LipidTox for 
30 min at 4°C. Immediately after staining, flow cytometric measurements or FACS 
sorting were performed. For dead cell exclusion 7-AAD (7-amino-actinomycin D; 
Biolegend) was added to the stained cell suspensions, or cells were treated with a 
fixable live/dead cell reagent (Life Technologies) according to the manual. FACS 
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sorting was performed with 85 or 100 µm nozzles. The sorted cells were counted 
and processed for RNA isolation, cell culture or cytospin stainings. Single cell 
sorting was performed with the automated cell deposition unit (ACDU) directly in a 
24-well plate with 12 mm cell culture inserts (Millipore, 0.4 µm pore size). The 
following antibody mixtures were used for the different analysis: 
 
 Fgrf2b detection: 
Antibody Dilution 
CD24 PE-Cy7 (clone: M1/69, Biolegend) 1:200 
CD49f PE (clone: GoH3, Biolegend) 1:50 
EpCam APC-Cy7 (clone: G8.8, Biolgend) 1:50 
Fgfr2b (clone: 133730, R&D Systems) or corresponding 
isotype control IgG2A (clone: 54447, R&D Systems) 
150 µg/ml 
goat anti-rat IgG Alexa Fluor 647 (Invitrogen) 1:1000 
Influenza A virus nucleoprotein FITC (clone: 431, Abcam) 1:20 
Sca-1 PerCP/Cy5.5 (clone: D7, Biolegend) 1:50 
 
 Proliferation measurements: 
Antibody Dilution 
CD24 PE-Cy7 (clone: M1/69, Biolegend) 1:200 
CD49f PE or Pacific Blue (clone: GoH3, Biolegend) 1:50 
EpCam APC-Cy7 (clone: G8.8, Biolgend) 1:50 
Ki67 FITC or PE (clone: B56, BD Bioscience) and 
corresponding isotype control IgG1 κ FITC, PE (clone: MOPC-
21, BD Bioscience) 
undiluted 
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 Apoptosis measurements: 
Antibody Dilution 
Annexin V Alexa Fluor 647 (Invitrogen) 1:100 
CD24 PE-Cy7 (clone: M1/69, Biolegend) 1:200 
CD31 Alexa Fluor 488 (clone: MEC13.3, Biolgend) 1:50 
CD45 FITC (clone: 30-F11, Biolegend) 1:50 
CD49f PE (clone: GoH3, Biolegend) 1:50 
EpCam APC-Cy7 (clone: G8.8, Biolgend) 1:50 
 
 Measurement of mesenchymal cells: 
Antibody Dilution 
α-SMA FITC (clone: 1A4, Sigma-Aldrich) 1:100 
CD31 PE (clone: MEC13.3, Biolgend) 1:50 
CD45 APC-Cy7 (clone: 30-F11, Biolegend) 1:50 
CD90.2 APC (clone: 53-2.1, Biolegend) 1:100 
CD140a APC (clone: APA5, Biolegend) 1:100 
EpCam APC-Cy7 (clone: G8.8, Biolgend) 1:50 
Sca-1 Pacific Blue (clone: D7, Biolegend) 1:50 
 
 Sorting of type I and type II pneumocytes: 
Antibody Dilution 
CD24 PE-Cy7 (clone: M1/69, Biolegend) 1:200 
CD31 Alexa Fluor 488  (clone: MEC13.3, Biolegend)  1:50 
CD45 FITC (clone: 30-F11, Biolegend) 1:50 
CD49f PE (clone: GoH3, Biolegend) 1:50 
EpCam APC-Cy7 (clone: G8.8, Biolgend) 1:50 
Podoplanin APC (clone: 8.1.1, Biolegend) 1:20 
Sca-1 Pacific Blue (clone: D7, Biolegend) 1:50 
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 Sorting of leukocytes, mesenchymal cells, endothelial cells, epithelial cells 
Antibody Dilution 
CD31 PE  (clone: MEC13.3, Biolegend) 1:100 
CD45 FITC (clone: 30-F11, Biolegend) 1:50 
EpCam APC-Cy7 (clone: G8.8, Biolgend) 1:50 
Sca-1 Pacific Blue (clone: D7, Biolegend) 1:50 
 
 Sorting of human epithelial cells: 
Antibody Dilution 
CD24 PE-Cy7 (clone: ML5, Biolegend) 1.50 
CD49f PE (clone: GoH3, Biolegend) 1:50 
EpCam FITC (clone: HEA-125, Miltenyi Biotec) 1.50 
lgr6 Alexa Fluor 647 (Bioss), lgr6 (clone: EPR6874, LifeSpan 
Bioscience) 
1:20 
 
 Sorting of epithelial stem/progenitor cells, small airway epithelial cells and 
mesenchymal cells 
Antibody Dilution 
CD24 PE-Cy7 (clone: M1/69, Biolegend) 1:200 
CD31 Alexa Fluor 488  (clone: MEC13.3, Biolegend)  1:50 
CD45 FITC (clone: 30-F11, Biolegend) 1:50 
CD49f PE (clone: GoH3, Biolegend) 1:50 
CD104 Alexa Fluor 647 (clone: 346-11A, AbD SeroTec) 1:20 
EpCam APC-Cy7 (clone: G8.8, Biolgend) 1:50 
Sca-1 Pacific Blue (clone: D7, Biolegend) 1:50 
 
2.11 Murine lung epithelial cell isolation 
Mice were scarified by cervical dislocation, thorax was opened and the vena cava 
was disconnected. A small incision was made in the left ventricle, and a 21-gauge 
butterfly cannula (Ecoflo) was installed in the right heart chamber to perfuse the 
lung with 20 ml HBSS (Gibco) until the lung was free of blood. A small incision was 
made in the dissected trachea and a blunt end 21-gauge cannula (B. Braun) was 
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fixed with a 4-0 surgical thread (Ethicon). The lung was filled with 1.5 ml dispase 
(5,000 caseinolytic units/100 ml, BD Bioscience), removed, washed in HBSS 
(Gibco) and incubated in dispase (BD Bioscience) for 40 min at room temperature. 
The lung was transferred into a petridish (Corning) with DMEM/HEPES 0.01% 
DNase I (Serva) and the bronchial tree, heart and trachea were removed. Lungs 
were homogenized (gentleMACS, MACS Miltenyi Biotech) in 7 ml DMEM/HEPES 
0.01% DNase I (Serva) and afterwards incubated for 5-10 min while rotating 
(Heidolph). The cell suspension was filtered through 100 µm and 40 µm (both BD 
Bioscience) filters, followed by centrifugation (800 rpm, 8 min, 4°C). The pellet was 
recovered in 5 ml mAEC medium and the cell number was determined with a 
Neubauer chamber and trypan blue staining (0.4%, Gibco). By addition of mAEC 
medium, the cell suspension was set to 10 million cells/ml. According to the cell 
number the following calculations were performed for magnetic negative selection: 
 
Calculation of biotinylated antibody volumes: 
biotinylated anti-CD45 antibody (BD Pharmingen):  
 number of million cells x 0.45 x 2 
biotinylated anti-CD16/32 antibody (BD Pharmingen):   
 number of million cells x 0.45 x 1.5 
biotinylated anti-CD31 antibody (BD Pharmingen):    
 number of million cells x 0.2 x 2 
 
Calculation of magnetic bead volumes: 
A: Number of million cells x 0.65 
B: A/3 ml 
C: B x 50 µl 
 
The calculated antibody volumes were added to the cell suspension to bind to 
leukocytes (anti-CD45, anti-CD16/32) and endothelial cells (anti-CD31), followed 
by incubation for 30 min at 37°C. The cell suspension was washed twice with 
DMEM/HEPES. The cell pellet was resuspended in a determined volume 
(calculated in B) of DMEM/HEPES and added to the biotin-binding magnetic 
beads (Dynabeads, Invitrogen), calculated in C. Prior to cell depletion, magnetic 
beads were washed three times and resuspended in PBS-/-. The cell suspension 
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containing the magnetic beads (Dynabeads, Invitrogen) was incubated for 30 min 
at room temperature until the tube was placed in the magnetic separator 
(Invitrogen) for 15 min. After separation the suspension was removed and 
centrifuged for 8 min, 800 rpm at 4°C. The pellet  was recovered and purity was 
determined by flow cytometry. Cells were either cultured in mAEC medium or 
further processed for flow cytometric analysis or cell sorting. 
 
2.12 Isolation of primary human epithelial cells and fibroblasts  
Lung tissue was minced and extensively washed with hAEC medium, followed by 
dispase II digestion (2.5 mg/ml, Roche) in PII-solution for 180 min at 37°C. The 
cell suspension was filtered through 100 µm, 40 µm (BD Bioscience) and 20 µm 
(Millipore) pore size filters. Cells were centrifuged at 1,500 rpm for 20 min at room 
temperature and the pellet was resuspended in PII-solution with 0.25% DNase 
(Serva). Separation of erythrocytes and lung cells was achieved by ficoll density 
centrifugation (Ficoll Paque; Amersham Pharmacia Biotech). Therefore, 20 ml 
Ficoll was overlayed with 15 ml cell suspension and centrifuged at 2,500 rpm for 
15 min at room temperature. The interphase was collected and centrifuged at 
1,500 rpm for 15 min at room temperature. The pellet was resuspended in hAEC 
medium and cells were counted in a Neubauer chamber with trypan blue to 
exclude dead cells. Cells were centrifuged at 1,500 rpm for 10 min at room 
temperature and resuspended in MACS buffer (10 million cells/ 80 µl MACS 
buffer), followed by subsequent depletion of leukocytes by anti-CD45 magnetic 
beads (Miltenyi Biotech). 20 µl anti-CD45 beads were added to 10 million cells, 
respectively, and incubated for 15 min at 4°C until cells were washed with MACS 
buffer and added to a washed MACS column (Miltenyi Biotec) for magnetic 
separation. The flow through was collected, centrifuged at 1,500 rpm for 20 min 
and the pellet was recovered with hAEC medium. Cells were counted and purity 
was determined by flow cytometry. Viability was analyzed by trypan blue exclusion 
and was always >95%.  
For the isolation of primary human lung fibroblasts, cells were collected after ficoll 
density centrifugation, counted and seeded in well plates with Basal medium 2 to 
promote fibroblasts growth. Cells were passaged at a confluency of ~ 80% up to 4-
5 times until they were directly used for co-cultures or frozen in liquid nitrogen. 
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Therefore, the cells were treated with trypsin EDTA (Biochrom), washed with 
Basal medium 2 and transferred to cryotubes (Thermo Scientific) with Basal 
medium 2 and DMSO (Sigma-Aldrich) in a 1:1 ratio. Cells were frozen overnight at 
-80°C and stored in liquid nitrogen until they were thawn at 37°C and cultured in 
Basal medium 2. 
 
2.13 Culture of murine or human epithelial cells in 3D matrix   
FACS sorted cells were centrifuged at 1,200 rpm for 10 min. After pellet recovery, 
cells were counted with trypan blue to exclude dead cells. The respective cell 
number was resuspended in 50 µl EpiSPC basic or expansion medium and mixed 
with growth factor reduced matrix (BD Biosciences) in a 1:1 ratio. After the cell 
suspension was shortly mixed with a vortex, 90 µl of the cell/ matrix suspension 
were seeded in 12 mm cell culture inserts, with a pore size of 0.4 µm (Millipore), 
and placed in a 24-well plate (Greiner bio-one). The plate was incubated for 5 min 
at 37°C, 5% CO2 to solidify the matrix, followed by addition of 350 µl EpiSPC basic 
or expansion medium into the lower well chamber. The medium was changed 
every second day. For mono-cultures 1000 epithelial cells (murine or human), 
were seeded into the matrix. For co-cultures of epithelial stem cells with 
mesenchymal cells, endothelial cells or leukocytes, the cells were seeded in a 
1:100 ratio into the matrix. For cell reseeding (clonality assay) or RNA isolation, 
the inserts were washed two times with PBSMg+/Ca+ and a prewarmed enzyme mix 
composed of 3 mg/ml collagenase I and dispase (Boehringer, Gibco) in PBSMg+/Ca+ 
(Gibco) was added to the wells and inserts. After 15-20 min of incubation, the 
enzyme mix containing lung organoids was pipetted in a reaction mix tube and 
incubated at 37°C for 30 min, followed by extensive mixing with a 1 ml syringe. 
Cells were washed two times with respective medium, counted and reseeded as 
described above (93), or processed for RNA isolation. For ex vivo Fgf10 blockade, 
5 µg/ml of Fgf10 neutralizing antibody (clone: C17, Santa Cruz) or corresponding 
isotype control (normal goat IgG, Santa Cruz) were added to the medium, after 2d 
of culture. Images were taken with a Leica DM IL LED microscope and 
corresponding camera MC170 HD.  
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2.14 Influenza virus infection of murine and human epithelial cells in vitro  
FACS sorted human or murine epithelial cells were infected with A/PR8  (murine 
cells) or A/Hamburg/04/09 (human cells) with the indicated MOIs. Cells were 
washed, counted and inoculum was added and incubated for 1h at room 
temperature. Inoculum was removed and 10,000 cells were seeded in matrix with 
corresponding medium and were further incubated, as already described. In 
selected experiments, FACS sorted murine or human epithelial cells were infected 
in liquid culture. The cells were incubated in a 1.5 ml tube while rotating for 8h at 
37°C, 5% CO2 until they were processed for flow cytometry.  
 
2.15 In vivo treatment protocols 
2.15.1 Orotracheal or intraperitoneal applications 
Mice were pretreated with a subcutaneous injection of 0.05 mg/kg Atropinsulphate 
(0.5 mg/ml, B. Braun), 1:10 diluted in sterile 0.9% NaCl (Delta Select GmbH) with 
a 27-gauge cannula. Mice were anesthetized by intraperitoneal injection of 
ketamin/rompun (ketaminhydrochloride 100 mg/kg, Pfizer; xylazinhydrochloride 
16mg/kg, Bayer). Mice were transferred to a heating plate (37 °C) and their eyes 
were covered with salve (Bepanthene, Bayer). When mice showed no reflexes to 
pain, an injection port of a safety intravenous catheter (B. Braun) was 
orotracheally applied and mice were inoculated with 500 PFU (except where 
otherwise indicated) A/PR8 (H1N1), A/X-31 (H3N2), A/Hamburg/04/09 (pandemic 
H1N1) diluted in 70 µl sterile  PBS-/- or PBS-/- alone as mock control. In selected 
experiments, 5 µg of recombinant murine Fgf10 (R&D Systems) dissolved in 
sterile PBS-/- or PBS-/- alone was orotracheally applied after influenza virus 
infection. Intraperitoneal injections (i.p.) of 100 µl naphthalene diluted in corn oil 
(both Sigma-Aldrich) or corn oil alone was administered. For organ isolation of 
non-treated animals, mice were sacrified by cervical dislocation, after a short 
anesthesia with 4% isoflurane (Baxter). Mice were visited daily and scored for 
morbidity according to the approved protocol. A morbidity score of more than 20 or 
additional criteria, like cyanosis of the mucosa, gasping, apathy, low body 
temperature and loss of more than 25% body weight within two days leaded to the 
termination of an experiment. 
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2.15.2 Sample collection  
After the given time points mice were exsanguinated in anesthesia. In selected 
experiments, lung permeability was determined by intravenous (i.v.) injection of 1 
mg FITC-labeled albumin (Sigma-Aldrich) diluted in sterile 0.9% NaCl (B. Braun). 
After the incubation time, mice were anesthetized as previously described. The 
blood was collected from the vena cava with a 1 ml syringe (Dispomed). The 
trachea was dissected and a blunt 21-gauge cannula was fixed with a 4-0 surgical 
thread (Ethicon) and BALF was collected by intratracheal addition and retraction of 
PBS/EDTA. The BALF was centrifuged at 1,200 rpm for 10 min at 4°C and the 
supernatant was aliquoted. After the blood had clotted completely, it was 
centrifuged at 3,500 rpm for 15 min. The serum was collected, followed by 8 min of 
centrifugation until erythrocyte-free serum was left. The serum and BALF were 
aliquoted in 0.5 ml tubes and stored at -80°C. Lung permeability was determined 
by quantification of FITC fluorescence in BALF and serum with a fluorescence 
reader (FLX800, Bio-Tek instruments). A standard curve of FITC albumin was 
prepared by serial dilution of 1 µg to 0.1 pg. 
Lung homogenates were obtained by instillation of 1.5 ml dispase (5,000 
caseinolytic U/100 ml, BD Biosciences) through the trachea into the HBSS (Gibco) 
perfused lung, followed by incubation in dispase for 40 min. After removal of the 
heart, trachea and bronchial tree, the lung was homogenized (gentleMACS, MACS 
Miltenyi Biotech) in DMEM and 2.5% HEPES with 0.01% DNase (Serva) and 
filtered through 100 µm and 40 µm nylon filters. The single cell suspension was 
further processed for flow cytometric analysis and cell sorting or magnetic-assisted 
epithelial cell isolation.  
 
2.16 Statistics 
All data are given as mean ± SD. Statistical significance between 2 groups was 
estimated using the unpaired Student’s t test or ANOVA and post-hoc Tukey for 
comparison of 3 groups calculated with GraphPad Prism. A p value less than 0.05 
was considered significant. 
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3. Results 
3.1 Characterization of distal airway epithelial stem/progenitor cells in the adult 
murine lung  
3.1.1 Gating strategy of adult murine epithelial cell populations 
For the enrichment of distal airway epithelial stem/progenitor cells (EpiSPC) in 
lung epithelial cell populations, flow cytometric analysis was performed with 
established surface markers (92). In a first enrichment step, biotin-labeled 
endothelial cells and leukocytes were depleted by biotin-binding magnetic beads. 
The majority of the remaining lung cells expressed the cell surface marker 
epithelial cell adhesion molecule (EpCam; CD326) and integrin α6 (CD49f). 
According to the expression levels of these two surface markers, the epithelial cell 
population was fractionated in EpCamlowα6low and EpCamhighα6high (Figure 3). In 
combination with the surface marker CD24, further division of the EpCamhighα6high 
cell population was achieved in CD24 low and high expressing cells. Therefore, 
the murine epithelial cells were fractionated into three major subpopulations. The 
high frequent EpCamlowα6low population included 91.3 ± 1.8% of the EpCam+ 
population, whereas the EpCamhighα6highCD24low made up 1.7 ± 0.3% and the 
EpCamhighα6highCD24high comprised 6.3 ± 1.8 % of the EpCam+ population. 
 
 
 
Figure 3: Flow cytometric characterization and gating strategy of primary murine distal airway 
epithelial cells.  
CD45 and CD31 depleted lung homogenate of WT mice was analyzed with flow cytometry according to 
surface marker expression of EpCam, integrin α6 (CD49f) and CD24. Adult murine epithelial cells were 
fractionated into EpCam
low
α6
low
, EpCam
high
α6
high
CD24
low
 and EpCam
high
α6
high
CD24
low 
subpopulations. FSC; 
forward scatter; SSC, side scatter.    
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3.1.2 Characterization of epithelial stem/progenitor cells according to their 
proliferative response in vivo 
Progenitor cells are characterized by their ablity to self-renew after injury and 
thereby contribute to repair processes (62, 144). Therefore, the proliferative 
response was analyzed in different injury models in vivo by quantitative flow 
cytometry. In addition to the gating strategy to differentiate lung epithelial cells 
(Figure 3), a nuclear marker for proliferation (Ki67) was included (145). 
Measurement of the proliferative response after bronchiolar injury induced by 
naphthalene revealed high renewal capacity in the EpCamhighα6highCD24low 
population, as compared to EpCamlowα6low or EpCamhighα6highCD24high populations 
at d3 after treatment. At d10 after i.p. treatment, the proliferative response 
returned to baseline levels (Figure 4).  
 
 
Figure 4: Proliferative response of epithelial cell subsets after naphthalene injury. 
WT mice were treated with naphthalene or corn oil as a control. CD31
+
 and CD45
+
 cell subsets were depleted 
and the proliferative response of the different epithelial cell subsets was measured by quantitative flow 
cytometry and staining for Ki67 at d3 and d10 after i.p. treatment. Bar graphs represent mean ± SD of n=4 
independent experiments; *p˂0.05; **p˂0.01; ***p˂0.001; d, day. 
 
Further investigation of the proliferative response after severe influenza virus-
induced bronchoalveolar injury was performed (146). As shown in figure 5A, the 
highest proliferative response was observed in the EpCamhighα6highCD24low 
fraction. Analysis of different time points after infection revealed strong 
proliferation at d7 and d14 post infection, whereat baseline levels were reached at 
d21 post infection. A representative FACS plot of Ki67+ EpCamhighα6highCD24low 
cell subset after influenza virus infection is shown in figure 5B. Analysis of 
apoptosis rates by Annexin V staining of EpCam+ cells revealed injury resistance 
of the EpCamhighα6highCD24low population in A/PR8 infected WT mice at d7 post 
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infection (Figure 5C) which is a characteristic feature of lung progenitor/stem cells 
(144). Due to the ability of the EpCamhighα6highCD24low cell fraction to strongly 
proliferate after injury, the epithelial cell subset is defined as epithelial 
stem/progenitor cell (EpiSPC), as previously suggested (92, 93).  
 
 
Figure 5: Proliferative response and apoptosis rates of epithelial cell subsets after influenza virus 
infection.  
(A) WT mice were infected with 500 PFU A/PR8 and the proliferative response of epithelial cell fractions was 
measured at day 0, 4, 7, 14 and 21 post infection. CD31 and CD45 positive cells were depleted and Ki67 
positive cells were analyzed by flow cytometry. (B) Representative FASC plots of Ki67 and isotype stained 
EpCam
high
α6
high
CD24
low
 at d7 post infection. (C) Apoptosis rates were measured by flow cytometric analysis of 
Annexin V
+
 cells in in vivo infected WT mice at d7. At least three animals/group were analyzed. EpCam
low
α6
low
 
and EpCam
high
α6
high
CD24
high
 were compared to EpCam
high
α6
high
CD24
low
 (EpiSPC); *p˂0.05; **p˂0.01; 
***p˂0.001; d, day.  
 
3.1.3 Characterization of epithelial stem/progenitor cells according to endogenous 
marker expression  
Further characterization of the EpiSPC population was performed by flow 
cytometry and immunofluorescence stainings according to markers which are 
associated with known epithelial stem/progenitor cells (80, 85, 90, 92, 95, 102). 
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Flow cytometric analysis of CD104 (integrin β4) and Sca-1 (stem cell antigen-1) 
revealed an ubiquitous expression in the EpiSPC population (Figure 6A). 
Cytospins of FACS sorted EpiSPC showed a morphologically homogenous 
population with a relatively large nucleus and a dense cytoplasm after 
Pappenheim staining. Immunofluoresence staining of FACS sorted EpiSPC 
revealed co-expression of proSP-C and CC10 in an EpiSPC subpopulation (Figure 
6B) as described for the BASC stem cell phenotype (90).  
 
 
Figure 6: Characterization of EpiSPC according to endogenous marker expression. 
(A) EpCam
high
α6
high
CD24
low
 cells were analyzed for expression of CD104 (integrin β4) and Sca-1 by flow 
cytometry. (B) Either Pappenheim or immunofluorescence stainings were performed with FACS sorted 
EpCam
high
α6
high
CD24
low
 cells with the indicated antibodies; EpiSPC, epithelial stem/progenitor cells.  
 
Further investigation of Krt5 and p63 expression in WT non-infected and influenza 
virus infected mice was performed by immunofluorescence stainings and qRT-
PCR. These markers were shown to be expressed by a so-called DASC (distal 
airway stem cell) population, which strongly contribute to repair processes and 
give rise to alveolar and bronchiolar lung tissue (98, 99). Another report described 
the contribution of lineage-negative epithelial progenitor cells (LNEP) to the 
p63/Krt5 repair program (99). Additionally, these markers are present in basal cells 
in the tracheal tissue (71). To investigate the Krt5 and p63 expression in EpiSPC 
of non-infected WT mice, lung and trachea digestions were prepared, followed by 
the preparation of cytospins of FACS sorted EpiSPC and tracheal cells, which 
served as a positive control. Immunofluorescence stainings showed high 
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expression of Krt5 and p63 in the tracheal cell compartment as compared to 
stained FACS sorted EpiSPC of non-infected WT animals (Figure 7A). To 
investigate the Krt5 and p63 expression after influenza virus infection, WT mice 
were infected with A/PR8 and EpiSPC were FACS sorted at d14 post infection. 
mRNA expression levels of Krt5 and p63 were compared to sorted EpiSPC of non-
infected WT mice. Krt5 and p63 were highly upregulated in EpiSPC after influenza 
virus-induced injury, indicating a strong endogenous regenerative capacity and 
contribution to the Krt5 repair program. 
Figure 7: EpiSPC upregulate Krt5 and p63 during influenza virus infection. 
(A) Cytospins of tracheal digests and FACS sorted EpiSPC of non-infected WT mice were stained with p63 
and Krt5. (B) EpiSPC of A/PR8 infected WT mice were sorted at d14 post infection and compared to non-
infected sorted EpiSPC of WT animals. Krt5 and p63 expression levels were analyzed by qRT-PCR. Bar 
graphs show mean ± SD of n=4 independent experiments; **p˂0.01; ***p˂0.001.  
 
3.1.4 Characterization of the EpCamlowα6low and EpCamhighα6highCD24high 
populations 
Further characterization of the two remaining epithelial cell subsets was performed 
by cytospins of FACS sorted EpCamlowα6low and EpCamhighα6highCD24high cell 
subsets and Pappenheim stainings. A characteristic feature of the EpCamlowα6low 
population were large granular inclusions in the cytoplasm, which was likely to be 
surfactant protein stored in lamellar bodies (147, 148). Flow cytometric analysis of 
the EpCamlowα6low subset identified that the majority of these cells expressed 
proSP-C, a marker for type II pneumocytes (58). A minor fraction of EpCamlowα6low 
population expressed podoplanin (Figure 8A), indicating the presence of type I 
pneumocytes (149).  
To characterize the EpCamhighα6highCD24high population, cells were FACS sorted 
and cytospins were made, followed by Pappenheim staining, which revealed 
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ciliated and non-ciliated cells (Figure 8B). Additionally, cells were cultured for 4d 
and stained for mucin5ac and β-tubulin, which revealed the presence of ciliated (β-
tubulin+) and goblet cells (mucin5ac+) (54, 150). Flow cytometric analysis showed 
that there is also a minor population of CC10+ cells, but no proSP-C+ cells. 
Together, these data revealed that EpCamlowα6low cells represented mainly 
alveolar epithelial cells (AEC) (type II and type I pneumocytes), whereas 
EpCamhighα6highCD24high cells were mainly composed of ciliated, goblet and club 
cells and were therefore termed small airway epithelial cells (SAEC). 
 
 
Figure 8: The EpCam
low
α6
low
 and EpCam
high
α6
high
CD24
high
 cell fractions included terminally 
differentiated lung epithelial cells. 
(A) Characterization of the EpCam
low
α6
low
 (AEC) cell subset with FACS sorted and Pappenheim stained 
cytospins or by flow cytometry with the indicated antibodies. (B) FACS sorted and Pappenheim stained 
cytospins of the EpCam
high
α6
high
CD24
high
 cells subset revealed cilliated (arrow) and non-ciliated cell fractions. 
Immunofluorescence stainings of FACS sorted EpCam
high
α6
high
CD24
high
 epithelial cells cultured for 4d and 
stained with mucin5ac and β-tubulin. Flow cytometric analysis of EpCam
high
α6
high
CD24
high
 epithelial cells with 
CC10 and proSP-C was performed.  
 
3.2 EpiSPC show organoid outgrowth, clonal expansion and terminal 
differentiation in 3D cultures 
To identify the proliferative capacity and clonality of EpiSPC in vitro, the different  
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epithelial cell fractions were FACS sorted according to the gating strategy in figure 
3, seeded in matrix and stimulated with hepatocyte growth factor (HGF) and 
fibroblast growth factor 10 (Fgf10) (Figure 9A). After 5, 8 and 14 days in culture, 
images were taken. EpiSPC responded to growth factors (GF) by proliferation and 
expansion which resulted in organoid outgrowth, as compared to AEC and SAEC. 
The clonality of EpiSPC was tested by serial passaging, therefore the matrix was 
digested and a single cell suspension of EpiSPC were reseeded with very low cell 
densities (  1000 cells/well), which again resulted in growth of organoids. The 
culture was repeatedly passaged for up to six times (Figure 9B). To further confirm 
the clonality of EpiSPC, a single cell sort was performed, which similarly resulted 
in organoid outgrowth (Figure 9C) and confirmed the robust clonogenic potential of 
EpiSPC. 
 
 
 
 
 
 
Figure 9: EpiSPC show high proliferative capacity and clonal expansion in the presence of growth 
factors.  
(A) AEC, SAEC and EpiSPC were FACS sorted and seeded in matrix. Medium was either supplemented with 
30 ng/ml hepatocyte growth factor (HGF) and 50 ng/ml fibroblast growth factor 10 (Fgf10) or left 
unsupplemented (w/o GF). Images were taken at d5, d8 and d14 after seeding. (B) Schematic illustration of 
serial passaging of the EpiSPC population in 3D culture. FACS sorted EpiSPC were seeded in matrix and 
supplemeted with HGF and Fgf10. After one week of culture, the matrix was digested and 1,000 cells were 
reseeded, which was performed for up to 6 weeks. (C) Single cell sort of EpiSPC was performed in matrix with 
supplemented medium. d, days; Fgf10, fibroblast growth factor 10; HGF, hepatocyte growth factor; w, weeks; 
w/o GF, without growth factors. 
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To determine the differentiation status of the EpiSPC in vitro, the matrix was 
digested after 10d of culture. RNA was extracted of cultured (d10) as well as 
freshly FACS sorted EpiSPC (d0), and analyzed for markers of differentiated cell 
types. Aquaporin 5 was significantly upregulated after 10d in culture, as compared 
to freshly sorted EpiSPC and in relation to flow sorted type I pneumocytes, defined 
by CD31negCD45negEpCamlowα6lowpodoplanin+. Moreover, also β-tubulin was 
upregulated after EpiSPC culture in relation to expression in SAEC indicating 
upregulation of bronchiolar, as well as alveolar markers and the multilineage 
potential of EpiSPC (Figure 10A, B).  
 
Figure 10: EpiSPC upregulate markers of terminal differentiated airway and alveolar epithelial cells in 
3D culture. 
RNA was extracted of FACS sorted EpiSPC (d0) and EpiSPC which were cultured in matrix for 10 days (d10) 
with growth factors. (A) Aquaporin 5 expression of EpiSPC was compared to freshly sorted type I 
pneumocytes. (B) β-tubulin expression of FACS sorted (d0) or cultured EpiSPC (d10) was compared to 
SAEC. Bar graphs represent mean ± SD of n=3 independent experiments; *p˂0.05; ***p˂0.001; d, days; ddCt, 
delta delta Ct; AEC I , Type I pneumocyte; SAEC, small airway epithelial cell. 
 
3.3 Gating strategy and 3D culture of putative human lung epithelial progenitor 
cells 
To identify a population of human lung epithelial progenitor cells (huEpiSPC) in 
distal airway tissue, healthy lung tissue was collected from lobectomy material. 
CD45+ cells of human lung digests were depleted and remaining cells were FACS 
sorted according to the surface marker expression, which was already established 
for the murine system (Figure 11). The EpCam+ epithelial cells were distinguished 
into EpCamlowα6low and EpCamhighα6high expressing cells, whereas the 
EpCamhighα6high population was further divided into a CD24low-neg and CD24+ 
fraction. Additionally, 95% of the EpCamhighα6highCD24low-neg fraction expressed 
lgr6 (leucine rich G protein coupled receptor), which is known to be expressed by 
epithelial progenitor cells in human lungs (66). FACS sorted 
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EpCamhighα6highCD24low-neg (huEpiSPC) showed organoid outgrowth in 3D cultures 
and were dependent on the growth factors HGF and Fgf10 (Figure 11C). 
 
 
Figure 11: Gating strategy of putative primary human epithelial progenitor cells and 3D culture.  
(A) Gating strategy of primary human epithelial progenitor cells, according to surface marker expression of 
EpCam, integrin α6 and CD24. (B) Flow cytometric analysis of the EpCam
high
α6
high
CD24
low-neg 
cells with lgr6. 
(C) 3D culture of FACS sorted EpCam
high
α6
high
CD24
low-neg 
primary human epithelial progenitor cells with and 
without addition of the growth factors HGF and Fgf10; ctrl, control; Fgf10, Fibroblast growth factor 10; HGF, 
Hepatocyte growth factor; w/o GF, without growth factors; FSC, forward scatter; SSC, side scatter. 
 
3.4 EpiSPC renewal capacity is dependent on the Fgf10/Fgfr2b axis after influenza 
virus infection 
To investigate the role of the Fgf10/Fgfr2b signaling pathway in the EpiSPC-
mediated proliferative response, different inducible transgenic or gene-deficient 
mice were infected with A/PR8 and the renewal capacity was measured by flow 
cytometry and Ki67 expression. Rosa26rtTA/+;tet(O)sFgfr2b/+ mice overexpressed 
a dominant negative, soluble receptor (sFgfr2b) after treatment with doxycyline-
containing food, which resulted in blockade of the Fgfr2b axis and decreased 
proliferative response of EpiSPC at d7 post infection (Figure 12A). Concomitantly, 
treatment of Rosa26rtTA/+;tet(O)Fgf10/+ animals with doxycycline-containing food, 
resulted in Fgf10 overexpression and led to an increased proliferative capacity of 
EpiSPC compared to mice which were fed with normal food (Figure 12B). Of note, 
Fgfr2b is able to bind Fgf10 as well as Fgf7 (112), therefore analysis of the 
proliferative response was performed using Fgf7 knockout mice compared to WT 
littermates. However, Fgf7 knockout mice showed only a slight, non-significant 
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decrease in EpiSPC proliferation (Figure 12C) which indicated that EpiSPC 
proliferation and renewal capacity was dependent on Fgf10 but not on Fgf7 in vivo. 
 
 
Figure 12: The proliferative capacity of EpiSPC is dependent on Fgf10 and the receptor Fgfr2b but not 
on Fgf7. 
(A) Rosa26
rtTA/+
;tet(O)sFgfr2b/+ (induction of soluble, dominant negative Fgfr2b) or (B) 
Rosa26
rtTA/+
;tet(O)Fgf10/+ mice (induction of Fgf10) were infected with 500 PFU A/PR8 and the proliferative 
response of EpiSPC, AEC and SAEC was measured with flow cytometry and Ki67 staining at d7 post infection 
in doxycycline treated mice (+dox) and in non-induced (-dox) animals. (C) The proliferative capacity of A/PR8 
infected Fgf7 knockout animals or WT littermates was measured with flow cytometry at d7 post infection. Bar 
graphs represent mean ± SD of at least n=4 animals/group; *p˂0.05; **p˂0.01; dox, doxycycline. 
 
3.5 Fgfr2b is upregulated on EpiSPC during influenza virus infection 
To address whether lung injury resulted in regulation of the Fgf10/Fgfr2b axis on 
receptor level, WT mice were infected with 500 PFU A/PR8 and Fgfr2b expression 
was analyzed on the EpiSPC population by flow cytometry at different time points 
post infection. The Fgfr2b surface expression was highly upregulated on EpiSPC 
at d5 and d7 post infection and reached baseline levels at d14 post infection 
(Figure13A). To evaluate if this effect was influenza virus-specific, quantification of 
Fgfr2b surface expression on EpiSPC after naphthalene treatment was performed 
(Figure 13B). At d3 after treatment a robust proliferative response was observed in 
the EpiSPC subset (Figure 4) and additionally, Fgfr2b expression was upregulated 
as compared to the control. However, the Fgfr2b upregulation was most prominent 
after influenza virus-induced injury, suggesting a particular involvement of Fgfr2b 
in repair after influenza-induced injury. 
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Figure 13: Fgfr2b is highly upregulated during influenza virus-induced injury. 
(A) WT mice were infected with 500 PFU A/PR8 or treated with sterile PBS
-/-
 as a control and Fgfr2b 
expression was analyzed by flow cytometry at d3, d5, d7 and d14 post infection on the EpiSPC subset. (B) 
WT mice were treated with either naphthalene or corn oil as a control. Fgfr2b expression was measured by 
flow cytometry at d3 after treatment. Values are given in MFI (median fluorescence intensity) normalized to 
non-treated WT mice indicated as dotted lines. Bar graphs represent mean ± SD of at least n=3 independent 
experiments. *p˂0.05; **p˂0.01; ***p˂0.001. 
 
3.6 EpiSPC outgrowth and differentiation is mediated by cross-talk with lung 
resident mesenchymal cells  
3.6.1 Characterization of lung resident mesenchymal cells 
To further elucidate the Fgf10/Fgfr2b cross-talk mechanisms, the predominant 
source of the Fgfr2b ligands in adult murine lungs was determined. To achieve 
this, fractionation of whole lung homogenate into the four main cell subsets was 
performed by sorting of epithelial cells (CD31negCD45negEpCam+), endothelial cells 
(CD31+CD45negEpCamneg), leukocytes (CD31negCD45+EpCamneg) and 
CD31negCD45negEpCamnegSca-1+ cells (151) (Figure 14A). mRNA expression 
analysis revealed that the Fgfr2b ligands Fgf7 and Fgf10 were predominantely 
expressed by cells gated in R4 of non-infected and A/PR8 infected WT mice 
(Figure 14B and C). Of note, neither Fgf7, nor Fgf10 mRNA were significantly 
increased after influenza virus infection. Previous data suggested that the 
CD31negCD45negEpCamnegSca-1+ population was associated with the fibroblast 
lineage (151). Further characterization of the R4 population revealed that ~ 5% 
expressed α-SMA representing myofibroblasts/smooth muscle cells, ~ 20% 
expressed CD90, a marker which indicate progenitor cells of the mesenchymal 
lineage, and ~ 12% were LipidTox+ PDGFRα+ indicative of a lipofibroblast 
phenotype (102, 129, 152, 153). Pappenheim stained cytospins of the flow sorted 
R4 population showed a morphologically homogenous population with large 
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cytoplasm. Cultured cells revealed an upregulation of α-SMA (smooth muscle 
actin) expression after 6d, suggesting that the CD31negCD45negEpCamnegSca-1+ 
population was composed of lung resident mesenchymal cells (rMC) with a 
fibroblast phenotype (Figure 14A).   
 
 
Figure 14: Characterization of lung resident mesenchymal cells and analysis of Fgfr2b ligand 
expression.  
(A) Representative flow cytometry plots (left) of the gating strategy to fractionate total lung homogenate of WT 
mice into endothelium (R1), leukocytes (R2), epithelium (R3) and Sca-1
high
 lung rMC (R4). Characterization of 
the Sca-1
high
 population according to mesenchymal cell markers was performed by flow cytometry (right 
panel). The FACS sorted Sca-1
high
 population was either Pappenheim stained or α-SMA  expression was 
analysed after 6d of culture. (B) mRNA expression of Fgf10 (C) or Fgf7 in FACS sorted lung cell populations 
was determined by qRT-PCR analysis. Bar graphs represent mean ± SD of at least n=3 independent 
experiments.  
 
3.6.2 Lung resident mesenchymal cells mediate EpiSPC expansion 
To investigate if Fgfr2b ligand-expressing rMC support organoid growth and/or 
differentiation of EpiSPC, FACS sorted rMC and EpiSPC were co-cultured in 3D 
matrix without growth factor supplementation (93). The presence of Fgf10-
expressing rMC was sufficient to promote the proliferative response of EpiSPC 
and the formation of organoids at d5 (Figure 15). Additionally, rMC supported 
saccular outgrowth of EpiSPC at d10 and the formation of lung-like structures at 
d16, as compared to growth factor supplemented EpiSPC mono-cultures (Figure 
9), or co-cultures with CD31+ or CD45+ cells (R1 and R2, figure 14), respectively. 
The role of the Fgf10-mediated cross-talk between EpiSPC and rMC was 
Results 
48 
 
addressed by the addition of an Fgf10 blocking antibody in the co-culture system. 
Treatment with the blocking antibody resulted in decreased proliferative response, 
at an early stage, which was indicated by reduced organoid outgrowth and showed 
the important role of Fgf10 in EpiSPC proliferation and outgrowth in the cross-talk 
with rMC.  
 
 
 
Figure 15: Lung resident mesenchymal cells promote EpiSPC organoid outgrowth which is mediated 
by Fgf10. 
(A) FACS sorted EpiSPC and rMC were co-cultured in 3D matrix without addition of growth factors. (B) CD45
+
 
leukocytes and CD31
+
 endothelial cells were co-cultured with EpiSPC without growth factor supplementation. 
(C) Co-culture of EpiSPC and rMC with a Fgf10 neutralizing antibody, compared to IgG control of n=3 
independent experiments. ab, antibody; GF, growth factors; IgG, Immunoglobulin; rMC, resident mesenchymal 
cells; w/o, without. 
 
To evaluate whether Fgf10-expressing rMC have an influence on the EpiSPC 
differentation capacity, RNA was extracted after 10d and 28d of EpiSPC mono-
cultures or EpiSPC-rMC co-cultures and expression levels of markers for 
differentiated airway and alveolar epithelium were analyzed and compared to 
freshly FACS sorted EpiSPC (Figure 16). Podoplanin, a marker for type I 
pneumocytes (149) was highly upregulated in the co-culture model as compared 
to EpiSPC mono-cultures after 10d of culture, suggesting that the rMC promoted 
differentiation into alveolar epithelium. After 28d of EpiSPC mono-culture, 
podoplanin was also highly upregulated, which suggested, that EpiSPC in mono-
culture differentiated much slower, than in the co-culture system. Similar to 
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podoplanin, β-tubulin was highly upregulated in the co-culture, as compared to 
mono-cultures, indicating that rMC may promote the differentiation of EpiSPC into 
ciliated airway epithelium (154). In contrast, cyclin D1, a marker for proliferation 
(155) showed less expression in co-cultures, which suggested that rMC rather 
promote differentiation compared to proliferation of EpiSPC at later stages of 
culture. 
 
 
Figure 16: EpiSPC differentiation is accelerated in co-cultures with rMC. 
FACS sorted EpiSPC were either mono- or co-cultured with rMC. Mono-cultured EpiSPC were supplied with 
HGF and Fgf10, whereas co-cultured EpiSPC were left unsupplemented. After 10d and 28d of culture, RNA 
was isolated and expression of (A) podoplanin, (B) β-tubulin and (C) cyclin D1 was analysed by qRT-PCR. 
Bar graphs show ddct values compared to freshly FACS sorted EpiSPC. Bar graphs represent mean ± SD of 
n=3 independent experiments; *p˂0.05; **p˂0.01; ***p˂0.001; rMC, lung resident mesenchymal cells. 
 
3.6.3 Human lung fibroblast cross-talk with huEpiSPC to promote organoid 
formation  
To investigate if primary human fibroblasts similary cross-talk with huEpiSPC, 
FACS sorted huEpiSPC (EpCamhighα6highCD24low-neg) were co-cultured with 
primary human lung fibroblasts, without addition of growth factors. Figure 17 
shows that lung resident human fibroblasts supported organoid outgrowth of 
huEpiSPC, as observed by co-cultures of murine EpiSPC and rMC, suggesting a 
similar supportive phenotype of primary lung fibroblasts in the human lung. 
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Figure 17: huEpiSPC show organoid outgrowth in co-culture with primary human fibroblasts. 
Isolated primary human fibroblasts were co-cultured with FACS sorted huEpiSPC without addition of growth 
factors in matrix. Images were taken at day 5 and 10 after seeding. Representative images of n=3 
independent experiments. 
 
3.7 Influenza virus targets EpiSPC resulting in reduced proliferative capacity 
3.7.1 Ex vivo infection of EpiSPC results in reduced organoid formation 
To analyze the proliferative response and the ability to form organoids in 3D 
culture after influenza virus infection, FACS sorted EpiSPC were ex vivo infected 
with MOIs of 0.1 up to 5 and seeded in matrix. After 6d of culture, organoids were 
counted and revealed that higher MOIs of A/PR8 resulted in less organoid 
formation and decreased proliferative capacity (Figure 18A). Control staining with 
influenza virus NP after 8h of ex vivo infected EpiSPC revealed a robust infection 
rate of ~ 44% (Figure 18B).  
 
 
Figure 18: EpiSPC show impaired organoid formation after influenza virus infection.  
(A) Organoid formation in 3D culture was evaluated of FACS sorted and ex vivo A/PR8 infected EpiSPC with 
different MOIs at d6 post infection. (B) Representative FACS plots of ex vivo A/PR8 infected and NP stained 
EpiSPC after 8h showed an infection rate of ~ 44%. Bar graphs represent mean ± SD of n=3 independent 
experiments; *p˂0.05; **p˂0.01; ***p˂0.001; MOI, multiplicity of infection; ctrl, control; NP, nuceloprotein. 
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3.7.2 Influenza virus infected EpiSPC show reduced proliferative capacity and 
impaired Fgfr2b upregulation 
To investigate if an impaired reparative response after influenza virus infection is 
caused by the extent of EpiSPC infection, different influenza virus strains varying 
in their pathogenicity were analyzed. WT mice were infected with 500 PFU of low 
pathogenic H3N2 (x-31), pandemic H1N1 (A/Hamburg/04/09; pH1N1) causing 
mild to moderate injury and high pathogenic, mouse adapted A/PR8 (20, 156). 
After 21d post infection H&E stained lung sections of A/PR8 infected mice still 
showed alveolar wall thickening and impaired re-epithelialization (arrows), in 
contrast to x-31 or pH1N1 infected mice which represented an almost intact lung 
structure (Figure 19A). Interestingly, the pathogenicity of the different influenza 
virus strains correlated with EpiSPC infection rates, measured by influenza virus 
nucleoprotein (NP) staining in infected WT mice at d4 post infection (Figure 19B). 
Additionally, A/PR8 infected EpiSPC were limited in their proliferative response, 
indicated by reduced proliferation rates, measured by Ki67+ cell fractions of the 
corresponding epithelial cell subsets. Most importantly, the infected (NP+) EpiSPC 
cell fraction showed impaired Fgfr2b upregulation after influenza virus infection, as 
compared to the non-infected (NP-) EpiSPC cell fraction (Figure 19C, D), which 
indicated that the influenza virus-infected EpiSPC fraction were limited in their 
proliferative response due to impaired Fgfr2b upregulation. 
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Figure 19: The extent of EpiSPC infection correlates with the pathogenicity of different virus strains 
and the regenerative response is impaired by reduced Fgfr2b upregulation. 
(A) Lung sections were stained with H&E of mock-infected (PBS
-/-
) or influenza virus infected WT mice at d21 
post influenza virus infection. The different influenza virus strains varied in their pathogenicity from low (x-31), 
intermediate (pandemic H1N1) to high (A/PR8). Arrows indicate non-epithelialized areas. (B) WT mice were 
infected with 500 PFU A/PR8, pandemic H1N1 or x-31, respectively. Infection rates were determined with NP 
staining by flow cytometry. (C) WT mice were infected with 500 PFU A/PR8 and the proliferative response was 
measured by Ki67 staining of infected and non-infected epithelial subpopulations. (D) Fgfr2b
+
 EpiSPC were 
subdivided in infected (NP
+
) and non-infected (NP
-
) by flow cytometry at d7 post A/PR8 infection of WT mice. 
Bar graphs show mean ± SD of at least n=3 independent experiments; *p˂0.05; **p˂0.01; ***p˂0.001; NP, 
nucleoprotein. 
 
3.7.3 Ex vivo infection of primary human epithelial cells results in reduced cyst 
formation 
To investigate if primary huEpiSPC were targeted by influenza virus, FACS sorted 
huEpiSPC were infected with different MOIs of the pandemic H1N1 influenza virus 
strain A/Hamburg/04/09. Infection of huEpiSPC resulted in reduced proliferative 
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response, indicated by reduced organoid formation with increasing MOI in 3D 
cultures. The infection rate of ex vivo infected huEpiSPC was measured with 
influenza virus NP staining by flow cytometry and revealed to be ~ 20% (Figure 
20A, B).  
 
Figure 20: HuEpiSPC show reduced organoid formation after ex vivo infection with influenza virus. 
(A) Organoid formation in 3D culture was evaluated of FACS sorted and ex vivo infected huEpiSPC with 
different MOIs at d6 post infection. (C) Representative FACS plots of ex vivo infected and NP stained 
huEpiSPC after 8h of infection showed an infection rate of ~ 20%. Bar graphs represent mean ± SD of n=3 
independent experiments; *p˂0.05;**p˂0.01; MOI, multiplicity of infection; ctrl, control; NP, nuceloprotein; 
pH1N1, pandemic H1N1. 
 
3.8 Targeting the Fgf10/Fgfr2b axis during influenza virus infection in vivo 
3.8.1 Fgf10/Fgfr2b blockade impairs lung regeneration and restoration of barrier 
function 
To evaluate the role of the Fgf10/Fgfr2b axis in lung regeneration and outcome in 
vivo, inducible, transgenic Rosa26rtTA/+;tet(O)sFgfr2b/+ mice were treated with 
doxycycline food to inhibit Fgfr2b signaling. After influenza virus infection, lung 
permeability of induced and non-induced mice was measured by i.v. administration 
of FITC-albumin and determination of the FITC fluorescence in BALF and serum. 
At d14 post influenza virus infection, the alveolar leakeage was increased in 
doxycycline-induced mice (Figure 21A). Additionally, induced mice showed an 
increased mortality rate compared to non-induced mice. Moreover, the weight 
curve revealed that induced animals did not fully recover after influenza virus 
infection (Figure 21B and C). However, analysis of virus titers in BALF at d7 post 
infection revealed no significant difference between induced and non-induced 
mice, indicating that morbidity and mortality differences were not associated to 
altered host defense (Figure 21D). 
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Figure 21: Blockade of Fgf10/Fgfr2b signaling results in increased lung permeability, morbidity and 
mortality. 
Rosa26
rtTA/+
;tet(O)sFgfr2b/+ animals were infected with A/PR8. Doxycycline induced animals (+ dox) 
overexpressed soluble, dominant negative Fgfr2b and were compared with mice with normal food (- dox). 
Alveolar leakage was measured (A) by i.v. injection of FITC-albumin and quantification of FITC fluorescence in 
serum and BALF. (B) Induced and non-induced mice were analysed for their survival rates in % (Kaplan-Maier 
curve; n=8 respectively) and their corresponding body weight loss in % (C). (D) Virus titers were determined in 
BALF of induced and non-induced mice at d7 post infection of n=5 independent experiments. Bar graphs 
represent mean ± SD; *p˂0.05; AU, Arbitrary units; BALF, bronchoalveolar lavage fluid; dox, doxycyline; PFU, 
plaque forming units.  
 
3.8.2 Therapeutic Fgf10 application restores lung barrier function and improves 
outcome after influenza virus infection  
To evaluate whether recombinant Fgf10 (rFgf10) treatment would improve 
outcome after influenza virus infection, orotracheal application of 5 µg rFgf10, 
diluted in PBS-/-, or sterile PBS-/- alone as control was applied in WT animals at d6 
after influenza virus infection. Measurement of the proliferative response by Ki67 
staining at d7 post infection revealed an enhanced proliferative response in the 
EpiSPC fraction of rFgf10 treated mice as compared to PBS-/- treatment (Figure 
22A). Additionally, the percentage of EpCam+ epithelial cells in lung homogenates 
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was increased after rFgf10 treatment at d14 post infection (Figure 22B). To 
evaluate if the enhanced proliferative response of EpiSPC was accompanied by 
decreased alveolar permeability, measurement of alveolar leakage by i.v. FITC 
albumin injection and determination of FITC fluorescence in BALF and serum at 
d14 post infection was performed, which revealed a significant decrease of  
alveolar permeability by a single dose of rFgf10. Moreover, the mortality rate of 
rFgf10 treated WT mice was decreased as compared to PBS-/- treated WT mice 
after influenza virus infection (Figure 22C and D).  
 
Figure 22: Therapeutic application of recombinant Fgf10 improves alveolar barrier function and 
survival. 
WT mice were infected with A/PR8 and treated with either 5 µg recombinant Fgf10 or sterile PBS
-/-
 at d6 post 
infection. (A) Flow cytometric measurements of Ki67
+
 cells in the different epithelial cell subsets at d7 post 
infection was analyzed. (B) EpCam
+
 epithelial cells were analyzed in total lung homogenates at d14 post 
infection.  Alveolar permeability (C) was measured  by quantification of i.v. injected FITC-albumin in serum 
and BALF. The mortality rate (D) of rFgf10 and PBS
-/-
 treated WT mice was analyzed of n=8 mice/group after 
influenza virus infection. Bar graphs represent mean ± SD of at least n=5 independent experiments; *p˂0.05; 
**p˂0.01; AU, Arbitrary units; rFgf10, recombinant fibroblast growth factor 10. 
 
Additionally, analysis of the lung structure in rFgf10 or PBS-/- treated WT mice after 
influenza virus infection revealed a reduced number of alveolar septa in PBS-/- 
treated mice (see lower magnification). At d21 post infection, the rFgf10 treated 
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mice showed re-epithelialization and restoration of the lung structure 
(arrowheads), in contrast to PBS-/- treated mice which still showed an increased 
area of non-epithelialized lung tissue (arrows) (Figure 23). To evaluate the lung 
structure in terms of proliferation and cell to cell contact re-establisment, lung 
sections were stained for the adherence junction protein E-cadherin and the 
proliferation marker Ki67 (Figure 24). rFgf10 treated mice showed robust E-
cadherin expression, as compared to infected and PBS-/- treated or mock-infected 
mice. Furthermore, increased Ki67 expression of rFgf10 treated mice revealed a 
prolonged effect of the rFgf10 treatment until d21.  
 
 
Figure 23: Influenza virus infected and recombinant Fgf10 treated WT mice show re-epithelialization in 
hematoxylin/eosin stained lung sections. 
WT mice were infected with A/PR8 and treated with either 5 µg recombinant Fgf10 or PBS
-/-
 at d6 post 
infection. Lung sections were obtained at d10 and d21 post infection and stained with Hematoxylin-Eosin. 
Arrows indicate areas of unrepaired non-epithelialized alveolar tissue. Arrow heads represent areas of re-
epithelialization; bars= 200 µm; rFgf10, recombinant fibroblast growth factor 10. 
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Figure 24: Influenza virus infected and recombinant Fgf10 treated WT mice show re-establishment of 
cell to cell contacts and prolonged proliferation.  
WT mice were infected with A/PR8 or mock infected with PBS
-/-
 (mock). Orotracheal instillation of infected 
mice was performed using either recombinant Fgf10 or PBS
-/-
 at d6 post infection. Lung sections were 
obtained at d21 post infection and immunofluorescence stainings for E-cadherin and Ki67 were performed and 
compared to mock infected WT animals; bars= 200 µm; rFgf10, recombinant fibroblast growth factor 10. 
 
To investigate the contribution of rFgf10 treatment on the Krt5 repair program, lung 
sections of PBS-/- or rFgf10 treated mice were stained for Krt5 after influenza virus 
infection. The Krt5 repair program was initiated in both treatment groups (Figure 
25), but enhanced Krt5 expression was observed in the mice which were treated 
with rFgf10, suggesting that Fgf10 enhances the Krt5-dependent repair program 
after influenza virus-induced injury, which was shown to be cruical for the 
regeneration of lung tissue (98, 99). 
 
Figure 25: Recombinant Fgf10 treatment increases the Krt5 expression after influenza virus-induced 
injury. 
WT mice were infected with A/PR8 and treated with PBS
-/-
 or recombinant Fgf10 at d6 post infection. At d21 
lung sections were stained for Krt5 and dapi; bars= 100 µm; rFgf10, recombinant fibroblast growth factor 10; 
Krt5, Keratin 5.  
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4. Discussion 
Influenza virus pneumonia is characterized by epithelial cell apoptosis resulting in 
increased alveolar permeability and infiltration of protein-rich fluid into the air filled 
alveoli impairing gas exchange. Structural and functional re-establishment of the 
distal alveolar epithelial barrier after severe influenza virus pneumonia is crucial for 
survival and recovery.  
This project demonstrates that distal epithelial stem/progenitor cells (EpiSPC) 
drive renewal processes after severe influenza virus pneumonia, which involves 
cross-talk with lung resident mesenchymal cells and Fgf10/Fgfr2b-mediated repair. 
Additionally, EpiSPC show high infection rates, correlating with the pathogenicity 
of different virus strains. Importantly, infected EpiSPC show reduced renewal 
capacity and impaired upregulation of the Fgf10 receptor Fgfr2b. Therapeutic 
application of recombinant Fgf10 after influenza virus infection enhances the 
proliferative response which leads to increased survival rates and improved lung 
function and structure. These data show that Fgf10 plays a cruical role in 
promoting the regenerative phenotype of EpiSPC which provides a new 
therapeutic approach after severe influenza virus infection. 
 
4.1 EpiSPC characterization and proliferative response  
It has been shown that the lung comprises different region-specific epithelial 
stem/progenitor cells in the tracheobronchial as well as in the distal compartment, 
which contribute to lung restoration after injury (63). Regeneration of the distal 
epithelial compartment was shown to involve different epithelial stem/progenitor 
cell populations, including p63+Krt5+ lineage-negative epithelial progenitors 
(LNEP), distal airway stem cells (DASC) (98, 99), an α6β4+ alveolar epithelial cell 
population or more lineage committed CC10+ and/or proSP-C+ epithelial cells (55, 
90, 92, 95, 97, 102).  
The analysis of a popuation with the signature EpCamhighα6highCD24lowβ4+Sca-1+ 
(EpiSPC) (92, 93) showed stem cell characteristics as identified by clonogenic 
potential, injury resistance and organoid outgrowth in the presence of growth 
factors including Fgf10. Of note, organoid outgrowth could only be observed in the 
EpiSPC population and was not observed for terminally differentiated AEC 
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(EpCamlowα6low) or SAEC (EpCamhighα6highCD24high) populations. The clonality 
was demonstrated by single cell sorting and clonal passaging which included 
digestion of organoids and reseeding of single cell suspensions with a low cell 
density (92). This could be performed for up to 6 passages until cystic outgrowth 
was dramatically decreased, possibly due to terminal differentiation of EpiSPC in 
culture. To test the differentiation potential of EpiSPC in vitro, cysts were digested 
after ten days in culture, RNA was extracted and qRT-PCR analysis of β-tubulin 
and aquaporin 5 revealed expression of terminally differentiated airway and 
alveolar markers, suggesting the potential of EpiSPC to contribute to bronchial as 
well as alveolar lineages (54, 56, 154). EpiSPC showed a high proliferative 
response after bronchiolar injury induced by naphthalene (84) and bronchoalveolar 
injury caused by influenza virus infection (19), in contrast to other distal lung 
epithelial cell populations. This suggests, that EpiSPC contributed to alveolar and 
bronchiolar repair processes, indicated by their proliferative capacity after 
naphthalene treatment and influenza virus-induced injury. In the influenza virus 
model, the proliferative response of EpiSPC was especially observed at d7 post 
infection, continued until d14 and reached baseline levels at d21 post infection. 
This renewal response was associated to a strong induction of the p63/Krt5 
regeneration program, which was highly upregulated after influenza virus infection 
and absent in FACS sorted EpiSPC of non-infected mice. Of note, the p63/Krt5 
repair program was found to be crucial for distal lung repair (95, 98, 99).  
Analysis of the EpiSPC profile revealed that a fraction of these cells co-expressed 
low levels of CC10 and proSP-C, suggesting that a part of these proliferating 
EpiSPC differentiated into more lineage committed cells of the alveolar or 
bronchiolar tissue. Conflicting data exsist on the contribution of lineage committed 
cells to repair programs after injury (97-99, 157). It was previously suggested that 
most of the p63+ cells which were found during repair processes derived from the 
CC10+ pool, whereas a recent report suggested that the p63/Krt5 repair program 
is initiated by lineage-negative cells (97-99). Another report highlighted the type II 
pneumoncytes as a progenitor for alveolar tissue after bleomycin injury (102). 
However, the proliferative response of type II pneumocytes in the EpCam lowα6low 
AEC subset was limited after influenza virus infection in vivo. This suggests that 
the contribution of different progenitor cell polulations which are involved in 
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alveolar repair processes is injury-specific, and dependent on the injury severity as 
well as microenvironmental factors.  
 
4.2 Characterization of human epithelial stem/progenitor cells  
In order to identify epithelial stem/progenitor cells (huEpiSPC) in primary distal 
human lung tissue, the same gating strategy which identified EpiSPC in the murine 
model was applied. Interestingly, analogies between human and murine epithelial 
cells were found. The human EpCamhighα6highCD24low-neg fraction was strictly 
dependend on growth factors, including Fgf10 and showed organoid outgrowth in 
3D cultures. Additionally, the majority of these cells were lgr6+, which was 
previously found to be expressed by an E-cadherin+ population in the adult human 
lung that was able to form bronchoalveolar tissue in kidney capsules. Of note, the 
E-cadherin+lgr6+ cells were a subpopulation of α6+ cells (103). Therefore, the E-
cadherin+lgr6+α6+ population may be included in the EpCamhighα6highCD24low-neg 
subpopulation. Nevertheless, it is necessary to define specific markers for 
huEpiSPC characterization to determine their differentiation potential to alveolar or 
bronchiolar tissue after injury.  
Ex vivo co-culture of primary human lung fibroblasts and huEpiSPC revealed a 
supportive phenotype of fibroblasts in the human system, although huEpiSPC co-
culture did not result in the formation of lung-like structures. This could be 
explained by the variability of patient samples, concerning both epithelial cells and 
fibroblasts or due to reduced differentiation capacity of the cells ex vivo. 
Nevertheless, these data clearly show that fibroblasts composed a 
miroenvironment required for huEpiSPC outgrowth.  
Furthermore, huEpiSPC were effectively infected by a pandemic influenza virus 
strain, and whether pathogenicity of different virus strains also affects the infection 
rates of huEpiSPC needs to be addressed in future studies. 
 
4.3 The Fgf10/Fgfr2b axis during influenza virus infection  
It has been described that the Fgf10/Fgfr2b pathway plays a crucial role during 
lung development. Fgf10 and Fgfr2b knockout mice are not viable due to failure of 
organ formation which includes the absence of distal lung tissue (120-122). The 
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Fgf10/Fgfr2b pathway is usually inactive in adults but it has been shown that this 
pathway can be reactivated after naphthalene injury (134). To evaluate the impact 
of Fgf10 during influenza virus infection, the proliferative response was analyzed in 
different inducible transgenic animals. Rosa26rtTA/+; tet(o)sFgfr2b/+ or Rosa26rtTA/+; 
tet(o)Fgf10/+ mice either express a dominant negative, soluble Fgfr2b (sFgfr2b) 
which block the ligands before binding to cell-adherent Fgfr2b and therefore 
prevent Fgfr2b signaling, or overexpress the ligand Fgf10. Moreover, the 
proliferative response in Fgf7 knockout animals was investigated, since Fgf10 and 
Fgf7 share the same receptor (123, 124).  
Evaluation of Ki67+ cells showed that Fgf10 had a crucial role in the proliferative 
phenotype of the EpiSPC. Fgfr2b blockade resulted in reduced EpiSPC 
proliferation. Additionally, Fgf10 overexpression displayed an increased EpiSPC 
renewal capacity. The Fgf7 knockout animals only showed a slight, non-significant 
decrease in the EpiSPC proliferation, which lead to the conclusion that EpiSPC 
proliferation clearly depends on Fgf10 after influenza virus infection. Although Fgf7 
also acts as a ligand for Fgfr2b (124, 128), Fgf7 deficiency has not such a fatal 
effect during lung development (120, 125). Another report highlighted the different 
function of the two ligands with respect to Fgfr2b signaling and recycling. Fgf7 
stimulation leads to rapid receptor degradation, whereas Fgf10 receptor binding 
leads to recycling and prolonged signaling (128), suggesting ligand-specific effects 
on the EpiSPC renewal capacity and importance of the Fgf10 induced receptor 
maintainance on the cell surface. Evaluation of Fgfr2b surface expression on 
EpiSPC during influenza virus infection revealed an upregulation of the receptor 
especially during the acute phase of the infection. In naphthalene treated mice, the 
effect of Fgfr2b upregulation was moderate, indicating an injury-specific response 
with particular engagement of the Fgf10/Fgfr2b axis after influenza virus-induced 
injury.  
 
4.4 Lung resident mesenchymal cells mediate EpiSPC expansion 
During lung development, the Fgfr2b ligands Fgf7/10 are expressed by 
mesenchymal cells (158). With respect to the cellular source of the Fgfr2b ligands, 
the EpCamnegCD31negCD45negSca-1high popluation was found to primarily express 
Fgf7/10. Further characterization of the EpCamnegCD31negCD45negSca-1high 
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popluation revealed a mixture of α-SMA+ cells, a marker for myofibroblasts/smooth 
muscle cells, resident mesenchymal cells which may have stem cell potential 
characterized by CD90, and LipidTox+ PDGFRα+ indicating lipofibroblasts (102, 
129, 152, 153). Of note, Fgfr2b ligand expression did not remarkably change in 
non-treated and influenza virus infected mice suggesting that previously described 
Fgf10 upregulation in bleomycin and naphthalene treated mice (134) is an injury-
specific observation. Moreover, it indicates that the Fgf10/Fgfr2b axis is mainly 
regulated by receptor, and not by ligand expression, during influenza infection.  
 
Given that Fgf10 plays a role in stem cell maintenance by preventing 
differentiation during development (130), and that Fgfr2b ligands are expressed by 
the mesenchymal lineage, co-culture of lung resident mesenchymal cells (rMC) 
and EpiSPC was sufficient to support organoid outgrowth and formation of lung-
like structures without growth factor supplementation. Of note, CD45+ leukocytes 
or CD31+ endothelial cells did not have any supportive effect on EpiSPC 
outgrowth. In accordance to the in vivo data, blockade of the Fgf10 signaling by a 
neutralizing antibody ex vivo resulted in reduced proliferative responses of EpiSPC 
at an early stage of cystic outgrowth. At later stages, EpiSPC formed organoid, 
lung-like stuctures and increased the expression of terminal differentiation 
markers. These data confirm that EpiSPC are able to contribute to the restoration 
of lung organoids by proliferation in vivo and differentiation ex vivo. Whether 
EpiSPC expansion and differentiation requires additional factors induced by Fgf10 
itself or other microenvironmental factors which are released during injury has to 
be elucidated.  
 
4.5 Influenza virus targets EpiSPC thereby limiting EpiSPC mediated regeneration 
by restriction of Fgfr2b upregulation 
To evaluate the impact of influenza virus infection on the proliferative capacity, 
EpiSPC were FACS sorted and ex vivo infected. EpiSPC showed high infection 
rates after 8h post infection. Increasing virus dose of A/PR8 (MOI 0-5) resulted in 
reduced organoid outgrowth and size after ex vivo infection demonstrating a 
reduced proliferative response. Of note, EpiSPC showed reduced apoptosis 
indicating resistance to injury and resulting in survival of previously infected 
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EpiSPC. Whether surviving EpiSPC reveal disturbed regeneration programs in 
forms of induction of aberrant repair responses later on, such as promotion of 
tissue fibrosis, needs to be addressed. 
Importantly, infection of EpiSPC prevented EpiSPC-mediated repair processes by 
impaired Fgfr2b upregulation, resulting in limited proliferative capacity of infected 
EpiSPC compared to the non-infected EpiSPC subset of the same lung. In 
addition to that, the pathogenicity of different virus strains correlated to the 
infection rates of EpiSPC, indicating a previously undefined factor for the 
pathogenicity of influenza virus strains. Whether a specific tropism to EpiSPC 
determines pathogenicity of different influenza virus stains is currently 
investigated.  
Recent data, obtained in this research group showed that influenza virus interferes 
with the β-catenin-dependent gene transcription by inhibition of Fgfr2b expression 
in the infected EpiSPC fraction and thereby limits the proliferative response. 
Additionally, culture of distal lung epithelial cells with a β-catenin activator resulted 
in reduced viral replication, whereas an inhibitor showed increased viral load. The 
activation of Wnt signaling pathways can result in activation of various cell 
signaling cascades which may be cross-connected and regulate differentiation, 
proliferation, polarity and migration (159). During lung development it has been 
demonstrated that Wnt/β-catenin signaling is upstream of the Fgf signaling 
cascade (160). Additionally, it has been demonstrated that β-catenin expression is 
inhibited during influenza virus infection, and active β-catenin is an important 
regulator of the antiviral immune response (161). In accordance to that, recent 
unpublished data support the observation that canonical Wnt/β-catenin has an 
anti-viral effect and inhibition of the Wnt/β-catenin represents an immune evasion 
strategy of the virus, which additionally impairs the EpiSPC regeneration program. 
 
4.6 Targeting the Fgf10/Fgfr2b axis during influenza virus infection  
To elucidate the role of the Fgf10/Fgfr2b axis during influenza virus infection in 
vivo, induced and non-induced Rosa26rtTA/+; tet(o)sFgfr2b/+ were infected and 
analyzed for weight loss, survival and alveolar permeability. The data demonstrate 
that inhibition of the Fgf10/Fgfr2b axis resulted in increased alveolar leakage, 
higher mortality rates and increased weight loss after influenza virus infection. 
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Additionally, the induced mice showed incomplete recovery, indicated by reduced 
weight gain. Due to the fact that the Fgf10/Fgfr2b signaling pathway was mainly 
regulated by receptor expression and not by altered ligand secretion, the effects 
observed in the Rosa26rtTA/+; tet(o)sFgfr2b/+ mice seemed to be moderate in 
comparison with recombinant Fgf10 (rFgf10) treatment after influenza virus 
infection, demonstrating a strong benefit in outcome. WT mice which were treated 
with either rFgf10 or sterile PBS-/- after influenza virus infection showed enhanced 
proliferative response, likely by targeting the Fgfr2bhigh, non-infected EpiSPC 
subset. Additionally, the alveolar permeability was reduced, and the survival rate 
increased. H&E stained lung sections confirmed re-epithelialization and restoration 
of distal lung tissue in rFgf10 treated mice. The establishment of cell to cell 
contacts was demonstrated by E-cadherin stained lung sections. These findings 
indicate that, even after severe influenza virus-induced injury, excess Fgf10 can 
promote alveolar and airway repair processes by enganging the non-infected 
EpiSPC pool. Moreover, the prolonged proliferative effect of rFgf10 treatment is 
shown by Ki67 stained lung sections, which may be due to Fgfr2b recycling and 
prolonged singnaling (128). Furthermore, rFgf10 treated mice showed increased 
Krt5 expression in the distal lung tissue, indicating that the p63/Krt5 expressing 
EpiSPC subset contribute to the expansion of Krt5+ cells during repair processes 
which are fostered by rFgf10 application.  
Altogether, these data demonstrate that influenza virus infection of epithelial 
stem/progenitor cells severely impairs their Fgfr2b-mediated regenerative 
response, and that therapeutic treatment of influenza virus pneumonia with rFgf10 
promotes epithelial renewal capacity. Fgf10 therefore represents a putative 
treatment to drive epithelial repair to re-establish lung structure and improve gas 
exchange after a severe influenza virus pneumonia (Figure 26). 
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Figure 26: Proposed model of the EpiSPC repair program after influenza virus infection. 
Highly pathogenic influenza virus infect a substantial fraction of EpiSPC, which results in reduced Fgfr2b 
upregulation and impaired epithelial repair, partially mediated by Fgf10-expressing resident mesenchymal 
cells. Therapeutic application of recombinant Fgf10 overcomes influenza virus-induced regeneration failure by 
engagement of Fgfr2b-expressing EpiSPC which increases proliferation and leads to barrier repair and 
improved survival with the involvement of the Krt5 repair program. 
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5. Summary 
Influenza virus pneumonia causes apoptosis of alveolar epithelial cells, disruption 
of the epithelial barrier and edema formation that affects gas exchange 
dramatically, resulting in the acute respiratory distress syndrome with poor 
outcome. The pathology of influenza virus-induced injury is well studied, but repair 
mechanisms of the distal lung epithelium, which may influence the outcome are 
not well understood. It has been demonstrated that epithelial progenitor cells in the 
adult murine lung can repopulate injured tracheobronchial or alveolar regions. 
Therefore, this project investigated repair mechanisms of distal epithelial 
stem/progenitor cell (EpiSPC) after severe influenza virus pneumonia. The 
EpiSPC express the surface markers EpCamhighα6highCD24lowβ4+Sca-1+. They 
highly proliferate after influenza virus injury, but show low apoptosis rates after 
infection as compared to other epithelial subsets. Characterization of their 
phenotype in ex vivo 3D cultures revealed that flow sorted EpiSPC clonally expand 
in presence of growth factors, including Fgf10, and upregulate markers associated 
with terminally differentiated bronchiolar and alveolar cells. Lung resident 
mesenchymal cells defined as CD45negCD31negEpCamnegSca-1high revealed to be 
the primary source of Fgf10, and supported lung-like outgrowth in the absence of 
further growth factors. During influenza virus infection, the Fgf10 receptor Fgfr2b 
was highly upregulated on non-infected EpiSPC, whereas the infected population 
poorly upregulated the Fgfr2b, resulting in severe limitation of their proliferative 
response. Interestingly, the pathogenicity of different influenza virus strains 
correlated with infection rates of EpiSPC in vivo, suggesting a causal relation 
between the extent of EpiSPC infection and their capacity to restore lung function. 
Targeting the Fgf10/Fgfr2b axis by induction of dominant negative soluble Fgfr2b 
in transgenic mice resulted in increased alveolar permeability, weight loss, and 
decreased proliferative capacity of EpiSPC. Application of recombinant Fgf10 
(rFgf10) as a therapeutic approach in the acute phase of influenza virus infection 
enhanced the proliferative response of EpiSPC, decreased alveolar leakage and 
improved survival rates. Additionally, lung sections revealed better resolution of 
inflammation and restoration of lung structure after rFgf10 application. In 
accordance with decreased alveolar leakage, staining of lung sections revealed 
improved cell to cell connections in the alveolar compartment. With respect to the 
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human lung, a population similar to EpiSPC, expressing EpCamhighα6highCD24low-
neglgr6+ was identified, which similarly depended on growth factors, including Fgf10 
and formed cystic spheres in 3D culture. As demonstrated in murine organoid 
cultures, co-cultures of human EpiSPC with primary human lung fibroblasts 
promoted outgrowth without addition of growth factors, whereas infection with 
pandemic influenza virus resulted in a reduced proliferative response.  
In conclusion, this work identifies Fgf10/Fgfr2b-dependent EpiSPC as primary 
drivers of lung regeneration after influenza virus-induced lung injury. Influenza 
virus-induced inhibition of Fgf10-mediated repair caused by influenza virus 
infection could be overcome by therapeutic application of Fgf10, highlighting this 
approach as putative therapy for patients with influenza virus-induced ARDS. 
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6. Zusammenfassung 
Influenzaviren infizieren vorwiegend die Epithelzellen der oberen Atemwege. 
Dennoch kann das Virus in den distalen Bereich der Lunge vordringen und 
Pneumonien verursachen, die schließlich zum akuten Lungenversagen führen. Die 
Reparatur und Wiederherstellung eines funktionstüchtigen Epithels ist deshalb für 
die Genesung des Patienten von besonderer Bedeutung. Dabei spielen epitheliale 
Progenitorzellen eine zentrale Rolle. Diese können nach einer Schädigung des 
Epithels proliferieren und zu alveolärem und/oder bronchialem Epithel 
differenzieren und somit die alveoläre Schrankenfunktion wieder herstellen und die 
Sauerstoffversorgung gewährleisten.  
In dieser Arbeit  wurde eine Progenitorzellpopulation mit der Oberflächensignatur 
EpCamhighα6highCD24lowβ4+Sca-1+ untersucht, die maßgeblich an der 
Regeneration des Lungenepithels nach einer Influenzavirus-induzierten 
Pneumonie beteiligt ist. Diese epithelialen Stamm/Progenitorzellen (EpiSPC) sind 
im Gegensatz zu terminal ausdifferenzierten Epithelzellen Apoptose-resistent. 
Durchflusszytometrisch separierte und in Matrix kultivierte EpiSPC bilden 
organoide Strukturen in Abhängigkeit von der Verfügbarkeit des 
Wachstumsfaktors Fgf10. Die Fgf10-abhängige Proliferation der EpiSPC konnte 
auch in vivo in verschiedenen transgenen murinen Infektionsmodellen gezeigt 
werden. Eine gezielte Inhibierung des Fgf10/Fgfr2b Signalweges führte in diesen 
Tieren zu verringerten EpiSPC-Proliferationsraten, wohingegen eine Aktivierung 
des Signalweges die Proliferationsraten erhöhte. Dabei stellte sich heraus, dass 
der Ligand Fgf7, der wie Fgf10 den Rezeptor Fgfr2b aktivieren kann, keinen 
Einfluss auf die Proliferationsraten der EpiSPC ausübt. Desweiteren wurde der 
Rezeptor Fgfr2b durch eine Influenzavirusinfektion verstärkt auf den EpiSPC 
exprimiert, wohingegen die Expression seines Liganden Fgf10 nicht massgeblich 
beeinflusst wurde. Die erhöhte Expression des Rezeptors wurde insbesondere auf 
nicht infizierten EpiSPC nachgewiesen, deren Proliferationsrate, im Gegensatz zu 
infizierten EpiSPC, erheblich verstärkt ist. Desweiteren weisen die EpiSPC in vivo 
eine hohe Infektionsrate auf, wobei diese mit der Pathogenität verschiedener 
Influenzavirus Stämme korreliert. In in vitro Ko-Kulturen mit primären, Fgf10-
exprimierenden mesenchymalen Zellen der Lunge konnte ein verstärktes 
Wachstum der EpiSPC beobachtet werden, das in Abhängigkeit von Fgf10 zur 
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Ausbildung von Lungenorganoiden führte. Eine gezielte Inhibierung des 
Fgf10/Fgfr2b Signalweges in vivo führte zu einer höheren alveolären Permeabilität 
sowie Mortalität. Behandlung mit intratracheal appliziertem rekombinantem Fgf10 
resultierte in erhöhten EpiSPC Proliferationsraten, sowie geringerer Mortalität. 
Desweiteren konnte die alveoläre Schrankenstörung verringert, und die 
Regeneration des distalen Lungengewebes verbessert werden. Im distalen 
humanen Lungengewebe konnte eine, den murinen EpiSPC entsprechende 
Progenitorzellpopulation mit der Oberflächensignatur EpCamhighα6highCD24low-neg 
nachgewiesen werden, deren Wachstum ebenfalls Fgf10-abhängig war.  
Zusammenfassend wurde gezeigt, dass der Fgf10/Fgfr2b Signalweg nach einer 
Influenzavirusinfektion eine wesentliche Rolle in der EpiSPC abhängigen 
Regeneration des distalen Lungengewebes spielt. Eine durch Influenzaviren 
hervorgerufene Inhibierung der Regeneration konnte durch eine gezielte 
Behandlung mit rekombinantem Fgf10 kompensiert werden. Diese Ergebnisse  
weisen darauf hin, dass eine Behandlung mit rekombinantem Fgf10 zu einem 
Therapieerfolg bei Influenzavirus-induziertem ARDS-Patienten führen könnte. 
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